Understanding antimicrobial and antiseptic resistance relationships in Staphylococcus aureus by Krause , Alexandra
Understanding antimicrobial and 
antiseptic resistance relationships 
in Staphylococcus aureus 
 
Alexandra Krause  
(BSc) 
 












Department of Microbiology and Immunology 








Staphylococcus aureus is an opportunistic pathogen that causes skin infections, bacteraemia, 
and endocarditis in humans. In New Zealand, the common lineage of S. aureus is the ST1 
lineage which harbours a fusidic acid resistance gene (fusC) on its chromosome and can carry 
the multi-drug resistance plasmid pNZAK1. pNZAK1 confers resistance to mupirocin (mupA), 
ampicillin (blaZ), and chlorhexidine (qacA). Chlorhexidine is a rapid and effective antiseptic 
widely used in healthcare to disinfect equipment and patients to prevent bacterial growth. The 
pNZAK1 plasmid encodes qacA, which produces a multi-drug efflux pump that can confer 
tolerance to chlorhexidine. The aim of this study was to investigate the maintenance of 
pNZAK1 in S. aureus 14487 using a continuous culture system to impose energy limiting 
conditions and examine the variation in antimicrobial sensitivity and viability. The second 
objective was to investigate the role of qacA using a ∆qacA mutant in antimicrobial sensitivity 
assays against an isogenic qacA+ wild-type, specifically looking at tolerance to biocides like 
chlorhexidine or benzalkonium chloride. Our results indicated that low levels of chlorhexidine 
can increase gene expression of qacA, mupA, and norA. Additionally, qacA can increase 
survival of bacteria under antimicrobial pressure from biocide mixtures like Trigene. These 
data also showed that pNZAK1 was highly stable (>94%) in S. aureus 14487 and was 
maintained even without selection pressure under generalised nutrient limitation. Bacteria that 
lost pNZAK1 (5-6%) were isolated and showed an increased antimicrobial sensitivity. To 
investigate key mechanisms of plasmid maintenance we focused on the bacteriocin lactococcin 
972, and the toxin/antitoxin system pepA1. By creating single gene knockouts we observed no 
change in pNZAK1 plasmid maintenance. These results suggest that pNZAK1 is a highly stable 
multi-drug resistant plasmid and that plasmid-encoded genes such as qacA can be induced by 
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Figure 1.1. Electron microscope image of Staphylococcus aureus. (Photo: Janice Haney 
Carr, Centers for Disease Control (CDC)) 
 
The genus Staphylococcus are a group of organisms which are members of the Firmicutes (1). 
Staphylococcus were discovered in 1880 from surgical pus by Dr. Alexander Ogston and were 
named Staphylococcus because of their grape-like clustered appearance under the microscope 
(2). The name Staphylococcus comes from the Greek staphyle (cluster, bunch of grapes) and 
kokkos (seed, grain, berry) (Fig. 1.1). These organisms can colonise the skin, nose and mucus 
membranes of humans, and animals, such as the teat of cows which can lead to mastitis (3). 
Staphylococcus are normal commensals that can protect the host by producing compounds 
which limit growth the growth of pathogens (4). Staphylococcus can cause fatal soft-tissue 
infections (including abscesses), known colloquially as ‘staph’ infections, respiratory 
infections, as well as food poisoning. Some strains are also know to produce Panton-Valentine 
leukocidin (PVL), alphahemolysin (also known as alpha-toxin) as virulence factors (5). PVL 
lyse white blood cells reducing the body’s ability to fight off the infection and alpha-toxin 
forms pores in human cells for instance; red blood cells or keratinocytes, leading to a more 
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serious ‘staph’ infection (5). Strains of Staphylococcus are also known to form biofilms on 
surgical implants, IVs, or even catheters, which allows the bacteria to evade the host immune 
response and become resistant to antibiotics as the cells enter stationary phase (5). There are 
more than 32 different species of Staphylococcus. The most significant species and the most 
well characterised species is S. aureus, a catalase- and coagulase- positive bacterium, classified 
as a facultative anaerobe (6). The facultative nature of this Gram-positive bacterium allows it 
to proliferate in aerobic and anoxic environments, switching between anaerobic metabolism 
and aerobic respiration (6). S. aureus is able to withstand high sodium chloride concentrations 
(0.5-13.5%), pH ranges of 4 to 10, and temperature ranges of 7˚C to 48˚C, with a temperature 
optimum of 37˚C (7). S. aureus can contain many antibiotic resistance elements like the 
SSCmec cassette found on the chromosome of MRSA (methicillin-resistant Staphylococcus 
aureus) (8). SSCmec encodes the gene mecA that confers resistance to methicillin by encoding 
an alternate penicillin binding protein (PBP) called PBP2a that irreversibly binds to b-lactam 
antibiotics (9).  
 
1.1.1. Staphylococcus aureus: hospital acquired infections  
 
S. aureus colonises approximately 30% of the human population on skin and nasal mucous 
membranes without adverse effects, such individuals then act as carriers (5). The ability of  
S. aureus to colonise a high percentage of the human population asymptomatically allows the 
spread of the organism within a community. However, S. aureus is also an opportunistic 
pathogen and can be highly infectious due to its many virulence factors, such as coagulase, 
protein A, and fibronectin-binding proteins (6). S. aureus is one of the major causes of 
nosocomial (hospital associated) infections, particularly in immunocompromised patients, 
where it causes skin infections, bacteraemia, toxic shock syndrome, and endocarditis (10). The 
ability of S. aureus to form biofilms allows it to persist and replicate on medical devices, 
contributing to hospital-acquired infections. These infections, once readily treatable, are 
becoming increasingly fatal due to a rise in antimicrobial resistance (AMR) (5). S. aureus 
isolates have become resistant to many clinically-relevant antibiotics, leading to outbreaks of 




1.1.2. Staphylococcus aureus: community associated infections   
 
Before antibiotics like penicillin were commonly available, minor scratches could potentially 
lead to a life threatening illness caused by Staphylococcus (12). As such, the increase of drug-
resistant strains of S. aureus circulating within the community pose a serious threat to the 
immunocompromised who are at risk of infection (12). Resistance elements like SCCmec, 
which encodes mecA that confers methicillin resistance, however, often come with a fitness 
cost associated with the carriage of these elements (13). Therefore, the limited level of 
antibiotic selection tends to favour non-MRSA staphylococcal strains in the community (12). 
The MRSA strain USA300 first came in to the spotlight in 2000 after a CDC investigation into 
a MRSA outbreak in football players (14). The same strain was also found to be the cause of 
outbreaks in prison communities around the USA (14). Community-acquired MRSA infections 
have increased over the past 20 years highlighting the potential health care burden of drug 
resistant S. aureus infections in communities (11,15).  
 
1.1.3. General mechanisms of antimicrobial resistance in S. aureus 
 
The rise in AMR observed in S. aureus isolates is due to the bacteria’s ability to acquire 
resistance to antimicrobials through horizontal gene transfer (HGT) and chromosomal 
mutations. Specific chromosomal mutations have been observed which can upregulate the 
expression of existing resistance mechanisms such as efflux pumps like NorA which encodes 
resistance to quaternary ammonium compounds like benzalkonium chloride and biguanidines 
such as chlorhexidine (16).  
 
1.1.4. Acquired resistance in S. aureus 
 
Acquired genetic elements can encode alternative genes that can bypass the target of an 
antibiotic (17). This occurs for example in the development of resistance to b-lactam 
antibiotics, such as ampicillin. This class of antibiotic targets the DD-transpeptidase activity of 
penicillin-binding proteins (PBPs) to prevent crosslinking of peptidoglycan and inhibit cell 
wall synthesis (18). S. aureus can acquire mecA, which encodes an alternative PBP, PBP-2a, 
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that has low affinity for b-lactams, or the blaZ gene which encodes a b-lactamase, an enzyme 
which cleaves the b-lactam ring of the antibiotic (19). These resistance mechanisms allows  
S. aureus to proliferate even in the presence of b-lactam antibiotics making it more difficult to 
treat (16). 
 
1.1.5. Current treatment of S. aureus infections 
 
Typically, MSSA infections are treated with oral b-lactam drugs, but MRSA tend to be resistant 
to b-lactam antibiotics such as methicillin due to the SCCmec element (20). The lincosamide 
antibiotic clindamycin is commonly used in uncomplicated soft-tissue infection (20). For most 
‘staph’ infections the abscess would be drained and sterilised with an antiseptic while the 
patient also received oral antibiotics, to reduce the risk of reinfection. For more long-term 
treatment of invasive Staphylococcus infection, IV b-lactam antibiotics for MSSA or IV 
vancomycin for MRSA are used (20).  
 
1.2. Biocide tolerance in pathogenic bacteria  
 
Biocides are compounds which have broad spectrum activity against various Gram-positive 
and Gram-negative bacteria (21). Biocides are used as antiseptics and disinfectants in hospitals, 
agriculture and the food processing industry (22). Commonly used compounds are biguanides 
(chlorhexidine) and quaternary ammonium compounds (benzalkonium chloride (BAC)), which 
are used as antiseptics to disinfect patients and healthcare environments (22). Antiseptic 
solutions like Trigene, which is a mixture of quaternary ammonium compounds like BAC, 
polymeric biguanide hydrochloride, and dodecylamine, are also commonly used as 
disinfectants (23). Given their critical role in human medicine, a number of these compounds 
are on the World Health Organisation (WHO) list of essential medicines. Unfortunately, due 
to the widespread and indiscriminate use of these essential biocide compounds it has generated 
an environment which fosters the growth of bacteria that can tolerate these compounds 






1.3. Chlorhexidine and other biocides  
 
Chlorhexidine (Fig. 1.2A) is a highly potent biocide with rapid bactericidal action against both 
Gram-positive, and Gram-negative bacteria and acts by disrupting the bacterial cell wall by 
interacting with negatively charged phosphate groups like teichoic acid (Fig. 1.2B) (24). When 
chlorhexidine is used at low concentrations it has a bacteriostatic effect causing disruptions to 
membrane integrity (26-27). At high concentrations chlorhexidine affects the cytoplasmic 
contents of the cell leading to swift bactericidal activity and cell death (26-27). Chlorhexidine 
is commonly used as an antiseptic on patients and hospital equipment to reduce flora levels 
and limit infection by pathogens (25,27-28). A study in the UK showed that handwash 
containing 4% chlorhexidine immediately reduced bacterial levels on the skin by 86% and by 
99.2% after 6 applications (6 hours) (29). This highlights the effectiveness of chlorhexidine 































Figure 1.2. Structure and mechanism of chlorhexidine. (A) shows the chemical structure of 
chlorhexidine and is from a study by Chapman et al. (30). (B) demonstrates the mechanism of 
action of chlorhexidine. Chlorhexidine binds to negatively charged phosphate groups in the 
bacterial cell wall triggering leakage of cell contents and cell death. (B) is modified from 





Chlorhexidine has been used as a disinfectant and antiseptic since the 1950s, and due to its 
effectiveness, relative low cost and safety it is listed by the WHO as an essential medicine 
needed in a healthcare setting (32). As such, it is crucial that we increase our understanding 
about the emergence of chlorhexidine tolerance in bacteria. 
 
1.3.1. Evolution of tolerance and resistance in bacteria  
 
When a bacterium becomes tolerant to a compound it is able to survive longer in the presence 
of that compound. The intense pressure to survive generates resistant mutants that become 
more prevalent in the population (33). Tolerance to biocides is a major issue because when a 
bacterium develops an elevated minimum inhibition concentration (MIC) or minimum 
bactericidal concentration (MBC). It then has the potential to acquire further genetic elements 
through horizontal gene transfer or mutations to further evolve its tolerance compound into 












Figure 1.3. Representation of potential ways tolerant and resistant mutants appear in a 
bacterial population over time. (A) Tolerant-mutants (Tol) appear in the population and are 
positively selected for in the presence of external pressure (e.g. biocides), eventually becoming 
dominant in the population. These tolerant isolates then acquire secondary mutations leading 
to the development of resistance (Res). (B) Tolerant mutant population appear initially and 
then dissipate in frequency simultaneously as the resistance mutant population develops and 





The increase in antiseptic and biocide tolerance is an issue as biocides are used to disinfect 
patients and surfaces in healthcare settings to reduce the bacterial load and limit patient 
infection. Biocide tolerance is not limited to just one organism, as it has been observed in many 
bacteria including both Gram-negative and Gram-positive pathogens including: E. coli, S. 
aureus, Listeria monocytogenes, and Enterococcus faecium (34). However, certain bacteria are 
more intrinsically resistant to membrane-based sanitisers like chlorhexidine or BAC such as 
Gram-negative bacteria, mycobacteria and spore-forming bacteria (35). The widespread use of 
disinfectants, especially in a clinical setting, has selected for resistant bacteria (36).  
 
1.4. The role of biocides in co-selecting for antibiotic resistance 
 
Recently, plasmid-encoded antiseptic tolerance genes such as qacA, which encodes the MDR 
efflux pump QacA, have been described as a mechanism of plasmid maintenance whereby the 
selective advantage of having a plasmid that carries biocide tolerance genes increases the 
plasmid carriage in the population (37). These well-maintained plasmids can then acquire 
antibiotic resistance genes such as mupA or blaZ and increase the amount of cross-resistance 
between antibiotics and antiseptics (37). 
 
 
Figure. 1.4. The mechanism and regulation of the QacA multidrug efflux pump. (A) 
Schematic representation of the QacA multidrug efflux pump with its proposed substrate range 
reproduced from Venter et al. (38). (B) Schematic overview of the QacA efflux pump and the 





In S. aureus, tolerance to chlorhexidine is mediated by the membrane embedded qacA-encoded 
multidrug efflux pump QacA (Fig. 1.4.) (40). QacA was discovered in the 1980s on the plasmid 
pSKI in S. aureus (41-42). QacA has a large range of potential substrates such as quaternary 
ammonium compounds like BAC, biguanides like chlorhexidine, diamidines such as 
pentamidine, and dyes like Ethidium bromide (42). QacA works through using the energy-
dependent proton-motive force to pump compounds out of the cell (42). qacA is regulated by 
qacR, which produces a gene product that represses qacA transcription (Fig. 1.4B) (43). 
Another important efflux pump NorA was discovered in 1986 in a Japanese hospital from a 
fluoroquinolone-resistant S. aureus strain (41). The MDR efflux pump NorA encoded by norA 
on the chromosome shares similar substrates to QacA, but also confers resistance to 
fluoroquinolone antibiotics (42). Similar to QacA, NorA is also part of the major facilitator 
superfamily of drug efflux pumps (41).  
 
Given the clinical importance of MDR S. aureus, the potential selection of qacA-positive 
bacteria by hospital antiseptics is a critical area for future investigation. Does the use of 
chlorhexidine in hospitals co-select for the other resistant genes in MDR S. aureus by selecting 
for bacteria carrying the qacA gene? Plasmids conferring antimicrobial resistance tend to be 
maintained when it is advantageous for the bacteria in that environment, due to the fitness cost 
of maintaining a plasmid in non-selective conditions (44). Bacteria that are not expending 
energy maintaining a plasmid have an advantage over those bacteria in the population when 
growing in an antibiotic-free environment (44). 
 
Decreased susceptibility to disinfectants is a major concern for human healthcare as a number 
of opportunistic pathogens which are tolerant to the concentrations of sanitisers used clinically, 
can also be resistant to many clinically-relevant antibiotics (36). A study by Climo et al. (2013) 
showed that daily bathing with 2% chlorhexidine over 6 months in the ICU reduced the amount 
of bloodstream infections and colonisation of multi-drug resistant organisms (45). However, 
when bacteria are tolerant to antiseptics like chlorhexidine it means that they could remain 
present on the patient and then could potentially infect the patient and cause a persistent drug 
resistant infection (22,45). Increased infection frequency intensifies the burden on the 
healthcare system, for example, strains of E. coli can be resistant to the disinfectant triclosan 
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(mediated through the AcrAB-TolC efflux pump) as well as the antibiotics chloramphenicol, 
erythromycin, imipenem, tetracycline, trimethoprim, and others (46). Isolates of  
L. monocytogenes can harbour a mechanism of BAC resistance, encoded by the BAC resistance 
cassette bcrABC, as well as genes mediating resistance to the antibiotics erythromycin, 
tetracycline, and trimethoprim resistance (47). P. aeruginosa has a tripartite efflux system 
encoded on its chromosome, MexAB-OprM, which plays an important role in the resistance to 
triclosan and chlorhexidine (38,48). As discussed efflux pumps are one of the main 
mechanisms that convey resistance to antimicrobial compounds e.g. AcrAB-TolC, MexAB-
OprM, QacA, and NorA (Fig 1.5) (38). Unfortunately, the use of chlorhexidine in burn patients 
to prevent infection has been suggested to select for resistance against last line antibiotics like 
colistin due to MexAB-OprM and the pmr operon, which controls lipopolysaccharide 
modification (38,48). A study by Pamp (2008) showed that P. aeruginosa mutants lacking 
either the MexAB-OprM or the pmr operon were unable to form an effective biofilm that was 
tolerant to colistin (48).  
 
Broadly, bacteria are able to develop resistance to sanitisers by gene acquisition through HGT, 
or mutating chromosomal genes involved in the synthesis of the cell membrane. One example 
of this has been observed in Gram-positive bacteria where increased peptidoglycan 
crosslinking, leading to a thicker cell wall was found to limit entry of biocides like CHX and 
























Figure 1.5. Multi-drug efflux pump schematic of QacA and MexAB-OprM, two 
independent systems which confer tolerance to antiseptics. QacA can be found in the Gram-
positive opportunistic pathogen S. aureus, while MexAB-OprM is found in the Gram-negative 
opportunistic pathogen P. aeruginosa. Both of these MDR efflux pumps confer resistance to 
antibiotics as well as antiseptics like chlorhexidine or triclosan. These two systems enable 
either S. aureus or P. aeruginosa to tolerate/survive antimicrobial challenge in healthcare 
settings. This figure is reproduced from Venter et al. (38). 
 
1.5. Spread of MRSA in New Zealand 
 
MRSA was first discovered in the Auckland region of New Zealand in 1975 (Fig 1.6) (15,50). 
Since 1991, the community reservoir of MRSA in New Zealand has been increasing (15), and 
in the last few decades, MRSA has spread throughout New Zealand (50). The spread of MRSA 
in New Zealand is due to a number of factors, including the overuse of antibiotics (especially 
topical antibiotic agents like fusidic acid), exchange of bacteria between community and 
healthcare settings, and international travel increasing imported resistant bacteria such as 
USA300 MRSA (50). In New Zealand, MSSA (methicillin-susceptible S. aureus) causes the 
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majority of both hospital and community infections, whereas MRSA infections occur at a lower 
prevalence. Between 2005 and 2014, the period-prevalence of MRSA in New Zealand 
increased from 12.9 to 23.8 MRSA-positive cases per 100,000 people. Most of these infections 
were community-acquired (51). CA-MRSA has started to change over the last decade in the 
New Zealand setting with an increasing number of clones becoming resistant to antibiotics 




Figure 1.6. A timeline of significant events in antimicrobial resistance in New Zealand. 
The South West Pacific (SWP) strain of MRSA appeared in New Zealand in 1992. Extended-
spectrum b-lactams (ESBL) producing Enterobacteriaceae were first isolated in 1994. 
Epidemic resistant MRSA (EMRSA-15) first emerged in 1995. Multi-drug resistant 
tuberculosis (MDR-TB) was first isolated in 1995. Extensively drug resistant tuberculosis 





In New Zealand, the ST1 lineages of MSSA and MRSA contain a chromosomal fusC gene 
(Fig. 1.7) (10,11). Fusidic acid inhibits S. aureus by binding to elongation factor-G (EF-G), 
inhibiting protein synthesis. The gene fusC encodes the FusC protein which blocks binding of 
fusidic acid to the drug target site in EF-G (52,53). The widespread use of fusidic acid in topical 
creams such as Fusidin (LEO) has provided a mechanism for increased selection of the fusC 
resistance gene in the S. aureus population (52). To be able to distinguish different sub-types 
of S. aureus into epidemiological lineages spa typing used the sequencing from the variable 
coding region from protein A in S. aureus (54). Spa t127 is highly resistance to fusidic acid in 
both MSSA and MRSA strains (Fig. 1.7). This is an issue as spa t127 is one of the predominant 
clonal lineages in New Zealand (55). 
 
Figure 1.7. Clonal selection of ST 1 lineage MSSA and MRSA fusidic acid resistant clones 
in New Zealand. S. aureus protein A (SPA) was used to differentiate different ST 1 lineage 
clones. This graph shows FA-S (fusidic acid – sensitive), FA-R (fusidic acid – resistant) MSSA 






1.6. Antimicrobial resistance mechanisms encoded on mobile genetic elements 
 
In addition to the chromosomal mediated fusidic acid resistance, the ST1 New Zealand  
S. aureus lineages can harbour a MDR plasmid designated pNZAK1, which contains blaZ, 
qacA, and mupA genes (Fig. 1.8). As described qacA encodes a multi-drug efflux pump QacA 
that exports a variety of antibacterial compounds and is part of the major facilitator superfamily 
of transport proteins (57). The gene mupA encodes an alternative isoleucyl tRNA synthetase 
(IleRS-2), conferring resistance to mupirocin (58). Isoleucyl tRNA synthetase helps to link 
nucleotide triplets to their corresponding amino acid to create a polypeptide chain in protein 
synthesis. A high amount of multi-locus sequence type ST 1 NZ isolates carry blaZ, qacA, and 
mupA on a plasmid as well as fusC on the chromosome (Fig. 1.9A) (59). An investigation by 
Carter et al. (2018) specifically looked at the genome of S. aureus 14487 which harbours 
pNZAK1 and fucC. This S. aureus strain is spa type t127 and CC1 (clonal complex 1). This 
spa type is one of the main clonal lineages in New Zealand, which is why the relationship 
between qacA and pNZAK1 is a major issue (59). 
 
1.7. pNZAK1, general information and genetic features  
 
The ST1 lineage of S. aureus commonly harbours the multi-drug resistant plasmid pNZAK1 
(Fig. 1.8). This circular plasmid is approximately 28 kb in size with a GC content of 33% (59). 
pNZAK1 is part of the pMW2-like family of S. aureus plasmids that are restriction type 1 (60). 
pMW2-like plasmids can contain the transposon Tn552 which encodes the resistance gene blaZ 
as well as blaR1 and blaI (60). The pMW2-like plasmids with Tn552 insertions are found 
worldwide including, Australia, New Zealand, the UK, and the USA (60). In New Zealand, 
isolates with a pMW2-like plasmid containing the Tn552 insertion were first observed in 1922 
(59). pNZAK1 closely resembles pMW2, but has also acquired a 7 kb insertion containing the 
genes; qacA, qacR, and mupA (55). The copy number of pNZAK1 is currently unknown, but it 
can be speculated that due to its large size of 27 kb the copy number would likely be low. 
Additionally, it is hypothesised that pNZAK1 is not highly conjugative (pers. comm. Dr. Glen 
Carter, Doherty Institute, Melbourne). S. aureus isolates that contained the qacA and mupA 
insertion were first recorded in New Zealand in 1991 (59). In New Zealand, the prevalence of 
qacA in S. aureus is 7%, however, as there is currently insufficient timescale data detailing 
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qacA carriage in New Zealand it is unknown if the prevalence of qacA is increasing or 
decreasing (55). The respective prevalence of fusC, mupA, and qacA in ST1 S. aureus lineages 
is illustrated in Fig. 1.9. Within New Zealand there is a high level of fusC carriage in the ST1 
lineage isolates, whereby approximately 40% of New Zealand S. aureus strains investigated 
were positive for fusC, mupA, and qacA (59). The population size of ST1 lineages in New 
Zealand is increasing, especially after 1991 with the appearance of pNZAK1 as seen in Fig. 
1.9. This suggests that the MDR plasmid pNZAK1 may be involved in the rise of the ST1  
S. aureus lineage within New Zealand.  
 
Figure 1.8. Schematic representation of the plasmid pNZAK1. Genes are denoted by 
coloured arrows. Genes of interest are as follows: the antibiotic resistance genes encoding 
resistance to mupirocin and b-lactam antibiotics (mupA and blaZ), the antiseptic resistance 
protein QacA (qacA), and two potential plasmid addiction mechanisms (lactococcin 972 
bacteriocin and pepA1). The mupA and qacA insertion segment is shown in blue. The 
transposon 552 insertion segment containing blaZ is shown in red (sequence information 





Figure 1.9. History of fucC, mupA, and qacA carriage in New Zealand ST1 S. aureus 
strains. (A) 179 ST1 NZ S. aureus genomes were investigated in a study by Carter et al. where 
this figure has been reproduced from (59). The black bar signifies carriage of the gene and the 
white bar indicates that the gene is not present in that strain. The colours used for each strain 
indicate the country of isolation dark green; NZ, yellow; Australia, blue; UK, red; Malaysia, 
light green; India, dark blue; Brazil, grey; Iraq, royal blue; France, purple, USA. (B) A bayesian 




1.8. The important role of addiction systems and plasmid maintenance in bacteria 
 
Plasmids are a source of genetic material that can be easily transferred between strains (61). 
Most bacteria tend to carry plasmid DNA, but the exact size of plasmids can vary dramatically 
from 1 kb plasmids to >100 kb (61). Small plasmids can be maintained at many hundreds of 
copies per cell, whereas larger plasmids may be limited to less than 10 copies per cell. Plasmids 
can encode advantageous genes providing a competitive edge in a niche e.g. encoding 
antibiotic resistance genes or metabolic genes (17). 
  
 
Figure 1.10. Plasmid maintenance in bacteria in selective vs non-selective environments.  
As bacteria divide, the daughter cells in the presence of a selective environment retain the 
plasmid, however, in the absence of selective pressure (non-selective environment) daughter 
cells progressively fail to inherit the plasmid, and it is lost in the population overtime. The 
diagram of cells shown as orange squares are either in the plasmid-selective environment or 
non-selective environment. The red arrow signifies selection and the blue arrows show no 
selection. The plasmid is shown as a blue circle, the genome is green.  
 
For bacteria to maintain plasmid DNA it imposes an energetic burden upon the cell. Therefore, 
if a plasmid is not useful it will not be maintained, and will be lost from the bacterial population 
(Fig. 1.10) (61). This process helps bacteria streamline their genome to prevent wasting energy 




1.8.1. Plasmid addiction (maintenance) systems (PAS) in bacteria 
 
Plasmid stability can be improved by the presence of resistance elements or addiction systems 
on the plasmid. There are many types of addiction systems found on bacterial plasmids 
including toxin/antitoxin (TA) systems, restriction modification systems, and bacteriocin 
systems (62). TA systems work by encoding a highly stable toxin as well as short-lived 
antitoxin, thus requiring constant production of the antitoxin to survive (Fig. 1.11) (62). Long-
lasting bacteriocin toxins are encoded in the plasmid as well as the immunity gene, which 
works to inhibit the function of the toxin (63). Restriction modification-based addiction 
systems use a restriction endonuclease that cleaves unmethylated DNA, the methyltransferase 
which methylates DNA, is encoded on the plasmid thus making the plasmid indispensable (62).   
 
Figure 1.11. Overview of the toxin/antitoxin plasmid addiction mechanism. This diagram 
highlights the two potential outcomes of the bacterial cell after cell division with and without 
plasmid maintenance systems. Either the cell maintains the plasmid post-segregation and the 
plasmid becomes established in the bacterial population and the cell survive; or, the cell loses 




The are many different types of TA systems in bacteria. A commonly studied TA system is the 
MazF/MazE system, which is a protein-based inhibitory system (62). MazF is the stable toxin 
which is inhibited by MazE, the unstable anti-toxin that is degraded by the ClpAP protease, 
meaning that the cell must continuously generate plasmid-encoded MazE to survive (62). 
Without MazE, MazF is able to bind to and cleave mRNA inhibiting protein production leading 
to the death of cells that lack plasmid-encoded MazE (62). Another type of TA system is 
antisense RNA systems like the pepA1 system which encodes SprA1AS and SprA1 (64). SprA1 
encodes pepA1, a cytotoxic peptide, which disrupts the cell membrane leading to host cell death 
(64). SprA1AS is the antitoxin which bind to the SprA1 RNA and prevents the creation of the 
deadly peptide pepA1 (64). When the antitoxin is encoded on the plasmid with the toxin it 
decreases the frequency of plasmid -ve cells in the population (62).  
 
Bacteriocins are toxic compounds excreted by specific strains of bacteria to hinder closely 
related strains, but not the host cell (65). The names of bacteriocin stem from the specific 
producing bacteria such as colicins from E. coli or lactococcins from Lactococcus lactis (65). 
Colicins bind to specific surface receptors on susceptible target strains of bacteria triggering 
cell death (65). Colicins have multiple subtypes with various mechanisms of action, colicin E1 
causes cessation of macromolecular generation, colicin E2 triggers degradation of genetic 
material such as DNA, and colicin E3 inhibits the generation of new proteins in the cell (65). 
However, the activity of a colicin is inhibited in the presence of a specific protein deemed the 
immunity protein, this protein allows the producing bacteria to survive.  
 
Another example of a bacteriocin is lactococcin 972 which inhibits cell division by preventing 
the formation of a septum in certain susceptible lactococcal strains by binding lipid II, a cell 
wall precursor molecule (66,67). This does not kill the cells immediately, but halts the cell 
cycle so that the cells are no longer growing (66). lactococcin 972 was shown to increase 
plasmid stability when the full lactococcin 972 operon is added to plasmids in Lactococcus 
lactis (67). The full operon consisted of lactococcin 972, and two other lactococcin 972 




 1.9. Energy limitation in bacteria 
 
Generalised nutrient limitation can impact the growth of a bacterial population, which then 
influences bacterial fitness. Alongside this the carriage of  extrachromosomal elements e.g. 
plasmid DNA can impose an additional energy burden (68,69). The chemostat first described 
in 1950 by Novick and Szilard (70) as well as Monod, (71), is a continuous culture vessel 
which allows precise control of bacterial doubling time, as well as the nutrient concentration, 
oxygen saturation and temperature of the growth conditions (Fig. 1.12) (68). The residence 
time (RT) of the chemostat is the time it takes for the reactor to completely exchange the media 
(RT = V/F) (72). The peristaltic media pump controls the dilution rate (dilution rate (D) = flow 
rate (F) / volume of reactor (V)). By changing the dilution rate, the bacteria are able to enter 
steady state at specially controlled growth rates (68). Additionally, when the chemostat has 
reached steady state the outflow of media and inflow of media are equal, meaning the volume 







Figure 1.12. Basic organisation of a functioning chemostat setup. A sterile media reservoir 
is controlled by a peristaltic media pump. The chemostat vessel is then filled with media at a 
specific dilution rate and waste is pumped through the effluent tube into the waste receptacle. 




Chemostats have previously been used to examine the effect of slow growth rate and hypoxia 
on the metabolism of Mycobacterium smegmatis (73). Additionally, the use of continuous 
culture has allowed studies to assess the fitness cost of the type I and type IV SCCmec 
resistance elements in MRSA (13). Earlier studies looking at the effect of bacterial stress 
responses on antibacterial sensitivity have found that the generalised nutrient limitation can 
enhance antibiotic resistance levels in bacteria, specifically for b-lactam antibiotics (74).  
 
The chemostat is the ideal tool for studying plasmid maintenance as it can be used to exert 
energy limiting conditions on bacteria while these organisms compete for limited nutrient 
sources. Very slow growth rates (imposed by the dilution rate) and competition for limited 
nutrients can activate stress proteins in the bacteria (75). Theoretically, this activation of stress 
proteins would then select for bacteria that have lost the plasmid, as it would be a fitness cost 
to maintain the plasmid under non-selective (e.g. lack of antimicrobials) conditions. The loss 
of the plasmid from the bacteria can be calculated by examining the increase in antimicrobial 






1.10. Overview of proposed work 
 
The overall aim of this research project was to elucidate the role of qacA in S. aureus 14487. 
This strain harbours an MDR resistance plasmid pNZAK1. This research investigated qacA 
specifically in regard to antiseptic tolerance. Additionally, we investigated the fitness cost 
associated with pNZAK1, and the role of two presumptive plasmid addiction systems, namely, 
lactococcin 927 and pepA1.  
 
Objective 1: Determine the role of S. aureus 14487 qacA in response to the antiseptic; 
CHX, BAC and Trigene. 
 
We hypothesised that the use of chlorhexidine selected for qacA and potentially the expression 
of other antimicrobial resistance genes (e.g. blaZ and mupA) encoded on the plasmid pNZAK1. 
We aim to further elucidate the role of qacA in S. aureus through the use of an isogenic ∆qacA 
knockout strain of S. aureus 14487. Antimicrobial sensitivity testing between wild-type  
S. aureus and ∆qacA S. aureus will be used to elucidate the conditions in which QacA is 
beneficial. To further understand the role of QacA, we examined the effect of antiseptics like 
chlorhexidine on gene expression of mupA, blaZ, qacA, as well as norA.  
 
Objective 2: Investigate the fitness cost associated with the plasmid pNZAK1 in S. aureus, 
under energy limiting conditions imposed by continuous culture (Chemostat) 
 
We propose that in the absence of antimicrobials, under energetically unfavourable growth 
conditions (e.g. energy limitation), the plasmid pNZAK1 comes with an energetic fitness cost 
to the host strain that will lead to plasmid loss. To further investigate the fitness cost of 
pNZAK1, wild-type S. aureus and S. aureus pNZAK1- were grown in a mixed culture and the 









Objective 3: Investigate the role of the presumptive plasmid addiction systems   
lactococcin 972 and pepA1 in pNZAK1 through the generation of double-cross over 
markerless single gene mutants. 
 
We hypothesis that the plasmid addiction systems lactococcin 972 or pepA1 found on pNZAK1 
play an important role in plasmid maintenance. To assess the possible role of lactococcin 972 














All commercial media used in this research was purchased from BD chemicals (Sparks, MD, 
USA), prepared according to the manufacturer’s specifications, and sterilised by autoclaving 




Dimethyl sulfoxide (DMSO) was purchased from Univar and stored at room temperature. 
Trizol was purchased from Ambion (Life Technologies) and stored at 4˚C. 
 
2.3. Antibiotic stock solutions 
 
All antibiotics, antiseptics and other chemical reagents were purchased from Sigma-Aldrich 
(New Zealand) unless specified otherwise. Chlorhexidine, fusidic acid, and ampicillin were 
dissolved in distilled water (dH2O) to 5.12 mg/mL, filter-sterilised using a 0.2 µm filter 
(Millipore Corporation, Bedford, MA, USA), and stored at -20˚C. Mupirocin was dissolved in 
DMSO to 5.12 mg/mL, filter-sterilised using a solvent suitable 0.2 µm filter (Ahlstrom) and 
stored at -20˚C. Chloramphenicol was dissolved in absolute ethanol to 100 mg/mL or 50 
mg/mL as required and stored at -20˚C. Benzalkonium chloride (BAC) was dissolved in filter 
sterilised dH2O to 30 mg/mL and stored at -20˚C. Trigene (Advanced), which consists of 
benzalkonium chloride, didecyldimethylammonium chloride and polyhexanide was purchased 
from Tristel Solutions limited and stored at room temperature. Rifampicin was dissolved in 
DMSO to 4 mg/mL and stored at -20˚C in microcentrifuge tubes covered in foil to prevent 




2.4. Long-term cryo-storage of bacterial cultures 
 
For the long-term storage of bacterial cultures, isolates were grown overnight before diluting 
with glycerol (final concertation of 87 % [v/v]) and stored in 1 mL volumes in sterile conical 
cryogenic tubes (NUNC A/S, Roskilde, Denmark) at -80 °C. When required, bacterial cryo-
culture stocks were propagated on the appropriate media in the absence of any antimicrobial 
and grown at 37˚C for 24 h. 
 
2.5. Bacterial strains and growth conditions 
 
The bacterial strains, and plasmids, used or generated in this study are described in Table 2.1. 
Staphylococcus aureus 14487, containing the plasmid pNZAK1, was isolated from Auckland, 
New Zealand and was kindly provided by Dr. Glen Carter (Doherty Institute, Melbourne). 
Unless otherwise indicated, S. aureus, refers to S. aureus 14487 containing pNZAK1. 
Typically, S. aureus was grown aerobically overnight (16 h) in cation-adjusted Mueller Hinton 
broth (MHB) at 37°C with agitation (200 rpm). For growth on solid media, MHB supplemented 
with 1.5% (w/v) agar (NZ Seaweed Ltd) was used (MHA). Tryptic soy broth (TSB) and Brain-
heart infusion (BHI) media were also used to grow S. aureus as required. Liquid broth cultures 
of S. aureus were prepared by inoculating a single colony into 5 mL MHB within a glass 
universal (30 mL) and incubated at 37˚C (200 rpm) until the desired optical density at 600 nm 
(OD600) was reached. S. aureus strains that lacked either the plasmid pNZAK1, or single gene 
knockouts of ∆qacA, ∆pepA1, or ∆lactococcin 972 (see Table 2.1) were grown under the same 
conditions as wild-type S. aureus 14487.  
 
Escherichia coli strains MC1061 and IMO8 B were used in this study for cloning (Table 2.1). 
The E. coli strains were treated the same as the S. aureus strains with the exception that they 
were propagated in Lysogeny (Luria) broth (LB) and as required solid media was prepared by 





Table 2.1. Bacterial strains used in this study  
Strain or plasmid Description  Source or Reference  
S. aureus   
14487 Clinical strain isolated from a patient in Auckland, NZ. PacBio sequenced. Contains pNZAK1 
plasmid 
(59) 
IM01 ∆qacA  S. aureus 14487 strain with pNZAK1 and a qacA markerless deletion  Doherty Institute of Melbourne 
AK01 pNZAK1-  S. aureus 14487 isolated from the chemostat (3 h) that lacks pNZAK1. Confirmed by whole 
genome sequencing (3-2-162) 
This study 
14487 rifR S. aureus 14487 that harbours pNZAK1 and spontaneous rifR  This study 
ATCC 6538 S. aureus strain that is MSSA and is the standard strain used for disinfectant susceptibility testing  (76) 
AK02 ∆pepA1 S. aureus 14487 harbouring pNZAK1 and a ∆pepA1 markerless deletion This study 
AK03 ∆bac S. aureus 14487 harbouring pNZAK1 and a ∆lactococcin 972 markerless deletion This study 
E. coli    
MC1601 E. coli strain used for cloning and plasmid propagation (77) 
IMO8 B E. coli strain with a restriction modification system recognised by S. aureus clonal complex 1 
(CC1) 
(78) 
Plasmids   
pNZAK1 MDR plasmid found in S. aureus. Contains ampR and mupR   (59) 
pKFC Cloning shuttle vector with BamH1 restriction sites. Contains ampR and cmR  (79) 
pbac_pKFC Cloning shuttle vector containing a ∆lactococcin 972 deletion. Contains ampR and cmR This study 
ppep_pKFC Cloning shuttle vector containing a ∆pepA1 deletion. Contains ampR and cmR This study  
 
 30 
2.6. Chemostat setup 
 
A 1 L chemostat (New Brunswick Scientific), with a 750 mL working volume containing ¼ 
strength MHB (to limit nutrients) was inoculated from an overnight culture of S. aureus to 
yield a starting OD600 of 0.05 (~2´107 CFU/mL). This culture was then grown in batch until an 
OD600 of 1.4 (or ¾ of maximum batch OD600 for MHB) before the media pump was turned on 
to a predetermined dilution rate (D) (73). In a more complex media, for example TSB, the 
maximum OD600 can be up to 11 in overnight batch culture of 100 mL (Fig. 3.3). At steady 
state, the specific growth rate (µ) of the bacterial culture is equal to D. The heating blanket was 
set to 37˚C. Dissolved oxygen was maintained at 50 % oxygen saturation, and the agitation 
was automatically (and continuously) controlled based on the measured dissolved oxygen 














Figure 2.1. A representative chemostat setup, using the chemostat continuous culture 
system from New Brunswick Scientific. S. aureus cells were routinely maintained in steady 
state at doubling times of 3 h (0.231 h-1), 10 h (0.0693 h-1), and 30 h (0.023 h-1).  



















2.7. Microbial and molecular analysis of the continuous culture (chemostat) 
 
2.7.1. Patch plating  
 
To determine the plasmid loss percentage of pNZAK1 within the S. aureus chemostat 
population, cell samples from the chemostat were withdrawn for each growth rate once steady 
state conditions had been confirmed. Steady state was confirmed after 3-4 residence times. The 
samples were then serially diluted 10-fold in sterile PBS. Following this, the 1´10-3 to 1´10-8 
dilutions were then spread plated (50 µL) in technical triplicate onto BHI agar and grown 
overnight at 37˚C. The CFU/mL for each dilution was recorded. Following this, 300 colonies 
were patch plated onto MHA, BHI agar, or MHA supplemented with ampicillin (6 µg/mL). 
The patch plates were then grown overnight at 37˚C. The patching plating was carried out in 
duplicate for each growth rate. No growth on ampicillin agar indicated loss of the host plasmid 
pNZAK1. 
 
2.7.2. Whole genome sequencing of presumptive plasmid loss isolates 
 
Isolates from the chemostat that were found to have lost resistance to antibiotics (mupirocin 
and ampicillin) through MIC and MBC testing were sent for whole genome sequencing at the 
Doherty Institute. To prepare the isolates for sequencing they were freshly streaked from cryo-
stocks onto agar. From this an overnight was prepared from a single colony. A new glycerol 
stock was then created from the fresh overnight. Glycerol stocks of each isolate were then sent 
to the Doherty Institute in Melbourne. DNA extraction and next-generation sequencing were 
performed at the Microbiological Diagnostic Unit Public Health Laboratory of the University 
of Melbourne. Genomic DNA was prepared from a culture grown from a single colony using 
a JANUS Chemagic workstation and Chemagic DNA/RNA kit (PerkinElmer, USA). DNA 
libraries were created using the Nextera XT DNA preparation kit (Illumina, USA). Next-





2.8. Determination of the minimum inhibitory concentration (MIC) by broth 
microdilution 
 
To determine the level of sensitivity to the antimicrobials: mupirocin, fusidic acid, ampicillin, 
and chlorhexidine the minimum inhibitory concentrations (MICs) were measured in biological 
duplicate and technical triplicate on samples withdrawn from the chemostat. All MICs were 
carried out in flat-bottom 96-well microtiter plates (ThermoFisher Scientific, New Zealand).  
At specific time intervals when S. aureus cells were in steady state, samples were removed 
from the chemostat and diluted to an OD600 of 0.0007, or ~2´105 CFU/mL (0.5 McFarland 
standard (McF). Bacterial culture (50 µL) was then added to wells of a 96-well microtiter plate 
containing two-fold serial dilutions of the antibiotic diluted in the appropriate media in a final 
volume of 100 µL. The compound range tested was 256 µg/mL to 0.125 µg/mL. In addition to 
the compounds being tested, media and compound vehicle controls were included in each 
microtiter plate. The microtiter plates were incubated aerobically for 24 h at 37˚C with shaking 
at 200 rpm. Photographs were taken of each of the MIC plates and the MIC was recorded as 
the lowest concentration of the test compound where no growth occurred.  
 
2.9. Determination of the minimum bactericidal concentration (MBC) 
 
To determine the bactericidal activity of mupirocin, fusidic acid, ampicillin, and chlorhexidine, 
the minimum bactericidal concentration (MBC) was determined from samples previously setup 
in MIC assays. To do so, 10 µL of culture from each well of the 96-well flat bottom microtiter 
plate was spot-plated onto a MH agar square plate, and the plates were incubated at 37°C for 
24 h. All MBCs were carried out in technical triplicate and biological duplicate, and the MBC 







2.10. Wild-type Staphylococcus aureus 14487 versus ∆qacA Staphylococcus aureus 14487 
cell viability assays 
 
The IMO1 ∆qacA strain was kindly provided by Dr. Ian Monk (Doherty Institute of 
Melbourne) (see Table 2.1). The deletion of qacA was confirmed by whole genome sequencing. 
  
Overnight cultures (5 mL) of wild-type S. aureus 14487 and ∆qacA mutant cells were used to 
inoculate three 100 mL TSB flasks to an initial starting OD600 of 0.05. These flasks were grown 
to mid-exponential phase (OD600 of 0.5 [~1x108 CFU/mL]) and challenged with 1´ the MIC of 
CHX (2 µg/mL). Samples were withdrawn at time 0 and subsequently at 0.5, 1, 2, 3, 4 and 24 
h. At each timepoint, 100 µl samples were withdrawn and diluted into ¼ MHB to determine 
the OD600. To determine the number of viable cells at each given timepoint, the Miles-Misra 
technique was followed (81). In brief, 10 µl samples were withdrawn, diluted 10-fold in 
phosphate buffer saline (PBS) to 1´10-8. Following this, 10 µl of the appropriate dilution were 
then spot plated onto TSA plates in technical triplicate. These plates were then used to calculate 
the CFU/mL of the culture at each time point.  
 
2.11. FDA compound screening  
 
S. aureus 14487 and the ∆qacA mutant cells were screened for inhibition of growth against the 
FDA-drug approved library (1399 compounds, Selleckchem, USA). Library compounds, 
dissolved in DMSO to 1 mM, were added at a final concentration of 25 µM to 96-well 
polystyrene microtiter plates (ThermoFisher Scientific, New Zealand) inoculated with either  
S. aureus 14487 or the ∆qacA mutant at OD600 0.05 (final volume 200 µL). The concentration 
of DMSO did not exceed 2% (v/v) and control wells containing 2% (v/v) DMSO were included 
in each plate. Additional control wells included: un-inoculated medium (TSB) and vancomycin 
(40 µg/mL). All controls were included in technical triplicate. Plates were incubated overnight 
at 37°C with agitation (200 rpm) and the OD600 were recorded using a Thermo Scientific 
Varioskan Flash plate reader. The inhibition of cells by FDA-compounds was determined by 
measuring the OD600 of treated cells, relative to untreated control cells. Assay performance was 
assessed by the statistical parameters Z and Z′, which take account of both data variability and 
signal window (82). Z′ is a measure of the suitability of the assay set up and takes in to account 
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the separation between negative and positive controls, Z-factor assess the impact of the 
screening library on the assay (82). 
2.12. Investigating the gene expression of specific genes in antiseptic challenged cells.   
 
2.12.1. Glycerol saline quenching preparation of cells for RNA extraction. 
 
S. aureus was grown in 5 mL MHB for 24 h and subsequently used to inoculate a 500 mL 
MHB flask to a starting OD600 of 0.05. To synchronise the cultures for compound challenge, 
the S. aureus culture was grown to an OD600 of 0.4 at 37˚C with shaking at 200 rpm. After 
which time the culture was then split into sterile flasks each containing 100 mL of synchronised 
culture. The cells were challenged with a given antimicrobial (e.g. 1 µg/mL CHX) for 1 h 
alongside an untreated control. Following this, an ice cold 3:2 glycerol:saline solution was 
added directly to the cells (i.e. 50 mL of cells to 100 mL glycerol:saline), which were then 
harvested by centrifugation at 25,900 ´ g for 20 min at 4˚C. The supernatant was removed and 
the washed cell pellet was resuspended in 1 mL of a 1:1 glycerol:saline solution. The cell 
suspension was then aliquoted into Eppendorf tubes (1 mL per tube) and snap frozen in a dry 
ice ethanol bath. The cell samples were then stored in cryo-culture at -80˚C. 
 
2.12.2. RNA extraction from S. aureus cells.  
 
Three washed glycerol:saline samples (1 mL) for each treatment type were centrifuged in a 
bench-top centrifuge at 16,300 ´ g, 20 min at 4˚C in technical triplicate. The supernatant was 
discarded, and the cell pellet was resuspended in 1 mL Trizol Ambion (Life Technologies). 
The cells were then disrupted by zirconium beads (0.1 mm) and a mini-bead beater (Biospec) 
at 4,800 oscillations per min for 30 s ´ 3, with a 30 s break between each disruption. Following 
disruption, the cells were transferred to a RNAse-free 1.5 mL Eppendorf and 200 µL of neat 
chloroform was added to the cells, followed by ‘hand shaking’ for 15 s. The cells were then 
incubated for 2 min and then centrifuged at 11,800 ´ g, at 25˚C for 15 min. The clear aqueous 
phase was then carefully transferred to a new Eppendorf and the RNA was then precipitated 
with 500 µL isopropanol (100% absolute) and centrifuged at 16,300 ´ g for 30 min at 25 ˚C. 
The supernatant was removed, and the pellet was washed in absolute ethanol (75 % [v/v]). The 
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cells were then washed again in absolute ethanol (75 % [v/v]) for 20 min at 8,900 ´ g and the 
supernatant was discarded. The RNA-containing pellet was air dried for 1 h at 25˚C and 
dissolved in 50 µL DEPC-treated MQ-H2O at 55˚C for 10 min. RNA (10 µg) was incubated 
with Turbo DNase buffer (Invitrogen), 2 µL of Turbo DNase and DEPC-treated MQ-H2O (50 
µL total volume) for 1 h. Following this, DNase inactivation reagent (20 µL) (Invitrogen), was 
added and the RNA was incubated for 5 min at 65˚C and centrifuged at 16,300 ´ g for 2 min. 
The supernatant was then transferred into an Eppendorf tube. The RNA concentration was 
measured via nanodrop (ThermoFisher Scientific, NZ) and was stored at -80˚C until required. 
 
2.12.3. cDNA synthesis  
 
For cDNA synthesis from RNA, 1 µg of RNA was added to an Eppendorf containing 1 µL of 
a 10 mM dTNP mix (Invitrogen), 250 ng of random primers (Invitrogen), and DEPC-treated 
MQ-H2O (final volume, 20 µL). The suspension was then incubated at 65˚C for 5 min, and 
cooled on ice for 1 min. Following this, 4 µL of 5´ First Strand Buffer (Invitrogen by 
ThermoFisher Scientific), 1 µL of 0.1 M DTT, 1 µL of RNaseOUT (Invitrogen) and 1 µL of 
SuperScript III Reverse Transcriptase (Invitrogen) was added to each reaction mixture. The 
cDNA was synthesised under the following conditions: 25˚C for 5 min, 50˚C for 1 h, with a 
final extension of 70˚C for 15 min. The cDNA was then stored at -20˚C until required.  
 
2.12.4. cDNA purity check  
 
To check for genomic DNA contamination in the RNA samples, a PCR was conducted in 
triplicate for each treatment group. The PCR contained cDNA, RNA, and a MQ-H2O control. 
PCR reactions were performed in 50 μL volumes with 1 µL of Phusion DNA polymerase 
(ThermoFisher Scientific) in accordance with the manufacturer’s instructions. PCRs were 
performed in a Hybaid PCR express machine, which had been preheated to 72°C. PCR mixes 
were held at this temperature for a further 2 min before commencing the PCR programme. 
Amplification consisted of one cycle at 98°C for 2 min and 30 cycles at 98°C for 15 s, 60°C 
for 30 s and 72°C for 20 s. This was followed by a final cycle consisting of incubation at 72°C 
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for 5 min. PCR products were then analysed by agarose gel electrophoresis (1% [w/v]), and 
documented electronically. 
 
2.13. RT-qPCR  
 
2.13.1. RT-qPCR primer efficiency 
 
Before RT-qPCR could be performed it was necessary to first check the efficiency of the primer 
pairs and the cDNA. Master mixes for each treatment type were created with Platinum SYBR 
Green qPCR-mix (Thermo Fisher Scientific), cDNA, ROX reference dye (Invitrogen), and 
MQ-H2O. The concentrations of cDNA used are listed in Appendix Table 4.4, and state the 
concentrations tested for: qacA, mupA, norA, blaZ, rho, and rrsC primers on each cDNA 
isolated from chlorhexidine treated and non-treated cells. The primer efficiency reaction was 
dispensed in a 96-well qPCR plate and was run in a ViiA 6 qPCR machine (Applied 
Biosystems). The CT value and cDNA dilutions were plotted to calculate the log of dilution 
(log 1/10). XY analyses were used to calculate the linear regression (slope) value for each 
primer pair. The slope value was entered into the ThermoFisher qPCR slope efficacy calculator 
to generate an efficiency value for each primer pair and cDNA concentration. The primer pair 
efficiency values are -1+10-1/slope, where a value of greater than 90 % indicates good primer 
efficiency. The qPCR primer pair efficiency values are shown in Table 4.1, and the exact 













2.13.2. RT-qPCR setup 
 
Following primer optimisation, a qPCR was conducted with 3 technical replicates for all 
treatment conditions. Reactions were carried out in a 96-well qPCR plate (Applied Biosystems 
by Life Technologies) on a ViiA qPCR machine (Applied Biosystems) with SYBER Green 
and ROX (ThermoFisher Scientific). The primers used were qacA, mupA, norA, blaZ, 
alongside the housekeeping genes rho and rrsC at 500 nM. rho and rrsC were used as control 
genes to calculate gene expression ratio according to the equation shown below:  
 






2.13.3. qPCR primer sequences  
 
Table 2.2. qPCR primer sequences 
Primer Name Forward primer sequences Reverse primer sequences 
qacA 5’-GTT GCA TCT GCT 
CTA ATA ATG-3’ 
5’-GGC TAC CAA GTA 
CTG CTA-3’ 
mupA 5’-ATC AGC ATT TTG 
GAA TAC TCA AA-3’ 
5’-TCA TGT GTA CAA 
TAA GGA GTC ACC T-3’ 
blaZ 5’-CCT GCT GCT TTC 
GGT AAG AC-3’ 
5’-TTC AGA TTG GCC 
CTT AGG AT-3’  
norA 5’-ATG CCT GGT GTG 
ACA GGT TT-3’  
5’- ATC CAC CAA TCC 
CTG GTC CT-3’  
Rho 5’-GGA AGA TAC GAC 
GTT CAG AC-3’ 
5’-GAA GCG GGT GGA 
AGT TTA-3’ 
rrsC 5’-CAT GCT GAT CTA 
CGA TTA CT-3’  
5’-CCA TAA AGT TGT 
TCT CAG TT-3’  
S. aureus 14487 primer sequences for genes tested in qPCR for gene expression.  
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No RT control Mix Volume 
DTT (0.1 M) 7 µL 
5´ First Strand buffer  28 µL 
MQ-H2O 118 µL 
Forward primer (10 µM) 1 µL 
Reverse primer (10 µM) 1µL 
DNase treated RNA (80-100 ng/µL) 1 µL 














cDNA Mix Volume 
Platinum SYBR Green qPCR Super 
Mix-UDG  
162.5 µL (1´ final) 
ROX passive reference dye 0.6 µL  
MQ-H2O  138.9 µL 
Forward primer (10 µM) 20 µL (500 nM final) 
Reverse primer (10 µM) 20 µL (500 nM final) 
cDNA (1/100)  3 µL 
Total volume 25 µL per well 
  
No cDNA, H2O Mix Volume 
Platinum SYBR Green qPCR Super 
Mix-UDG 
212.5 µL  
ROX passive reference dye 0.85 µL 
MQ-H2O  172.65 µL 
Forward primer (10 µM) 20 µL (500 nM final) 
Reverse primer (10 µM) 20 µL (500 nM final) 
cDNA (1/100)  0 µL 
Total volume 23 µL per well 
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2.14. DNA manipulation 
 
2.14.1. Commercial miniprep of plasmid DNA  
Small-scale plasmid preparations of plasmids were made using the Zyppy™ Plasmid Isolation 
Kit (Zymo Research) according to the manufacturer’s instructions. Plasmid DNA was eluted 
in 30 µL MQ-H2O. 
2.14.2. Agarose gel composition and gel electrophoresis  
 
Agarose gels were routinely run at either 100 V for 1 h in 1× TAE buffer (40 mM Tris-acetate, 
1 mM EDTA), using 1% (w/v) agarose (Invitrogen). Agarose gels were viewed on a UV 
transilluminator and photographed using an Alpha imaging HP system (Protein simple). 
 
2.14.3. Gel extraction 
 
DNA, both plasmid and genomic, was purified from 1% agarose (w/v) (Invitrogen) gels using 
the Zymo™ Gel Recovery Kit (Zymo Research) following the manufacturer’s instructions. 
DNA was eluted in MQ-H2O as appropriate. 
 
2.14.4. Sequencing  
 
All DNA and plasmid samples were purified as appropriate and sent to the Massey Genome 
Service for DNA sequencing. The samples were prepared to the specifications set out by 
Massey Genome Service. DNA sequences were analysed using the application Snapgene (GSL 
Biotech), and the programs BLASTN, BLASTP and BLASTX (National Centre for 








2.14.5. Primers  
 
The oligonucleotides used in this study are described in Table 2.2 and 2.5. Custom DNA oligos 
were ordered from Integrated DNA technologies (IDT). Primer stock solutions (100 µM) were 
routinely diluted in MQ-H2O to prepare either 50 µM or 10 µM working stocks. Primers were 
stored at -20˚C.  
 
2.14.6. Preparation of chemically competent E. coli cells 
An overnight culture (5 mL) of E. coli (MC1061) (Table 2.1) was grown in LB and 0.1 mL 
was used to inoculate 100 mL of LB. Cells were grown at 37°C with shaking at 200 rpm until 
an OD600 of 0.6-0.8 was reached. Once the target OD600 was reached, the culture was chilled 
on ice for 15 min and then transferred into 50 mL Falcon tubes, and harvested by centrifugation 
at 3,000 ´ g at 4˚C for 15 min. The cell pellet was resuspended in 100 mL of 0.1 M MgCl2 and 
incubated on ice for 5 min. Cells were then washed at 3,000 ´ g at 4˚C for 15 min. The pellet 
was subsequently resuspended in 50 mL of 0.1 M CaCl2 and incubated on ice for 45 min. 
Afterwards the solution was centrifuged at 3,000 ´ g at 4˚C for 15 min and the pellet was 
resuspended in 5 mL of 0.1 M CaCl2 and incubated on ice for 30 min. Sterile glycerol was 
added to a final concentration of 15% (v/v). The cell suspension was distributed into 100 µL 
aliquots and snap-frozen in liquid nitrogen. The aliquots were stored cells at -80˚C. 
2.14.7. Standard polymerase chain reaction (PCR) for colony screening 
 
In a 1.5 mL Eppendorf tube a single colony was resuspended in 30 µL MQ-H2O, or 30 µL of 
InstaGene matrix (Bio Rad) for S. aureus. The resuspended colonies were then incubated at 
95˚C for 15 min. Following this the cells were centrifuged at 16,300 ´ g in a bench-top 
centrifuge for 1 min. Standard screening PCR used Dream Taq Polymerase (ThermoFisher 























2.15. Construction of markerless deletion mutant 
 
Markerless deletion of target genes pepA1 and lactococcin 972 was carried out by double cross-
over homologous recombination using the shuttle vector pKFC (Fig 2.2 and Table 2.1) as 
described by Kato et al, (79). A diagram outlining the strategy used to generate markerless 
deletions is shown in Fig. 3.9, and the primer names and sequences used for this process are 
described in Table 2.1. In brief, using the shuttle vector pKFC, two homologous regions 
encoding upstream and downstream of the target genes pepA1 and lactococcin 972 were cloned 
into pKFC generating the two plasmids pbac_pKFC and ppep_pKFC (Table 2.1, and Section 
2.15.2-2.15.3). Following introduction into S. aureus (2.15.4) and integration into the host 
plasmid pNZAK1 (2.15.6), recombination events can occur in either the upstream or 
downstream region. Excision of target genes by the double-cross over leads to target gene 
Components Volume  
Dream Taq buffer  2 µL 
dNTPs 10 mM 0.4 µL 
Forward primer 10 µM  1 µL 
Reverse primer 10 µM 1 µL 
DNA template (~30 ng/µL)  0.5 µL 
Dream Taq Polymerase (5 U/µL) 0.2 µL 
MQ-H2O 14.9 µL 
Total 20 µL 
Temperature (C˚)  Duration  
95  3 min  
95 




30s per kb   
72 10 min  




deletion (see Section 2.15.5). This process generated the isolates AK02 (mutant lacking 







Figure 2.2. pKFC plasmid schematic. The shuttle vector pKFC (79) encodes 
chloramphenicol resistance (cat) in E. coli and ampicillin resistance (Amp) in S. aureus. The 
plasmid also carries a temperature-sensitive origin (ts ori) of replication derived from pE194ts. 
The ts ori allows straightforward genomic integration of pKFC at high temperatures (42°C). 




2.15.1. Markerless deletion cloning and gene primers  
Table 2.5. Cloning primer sequences 
Primer Name & Description       Primer sequences 
Bac1 
(Bacteriocin left flank forward)  
5’-AAAAAAGGATCCAAATGGACTTC 
TTCTTGGGG- 3’  
Bac2 


















(Integration left Bacteriocin pNZAK1 
reverse) 
 5’- TTGGTGAAGGTACCCATAAA-3’ 
Pep1 






















Table 2.5. Cloning primer sequences continued 
Pep6 
(Integration left pepA1 pNZAK1 reverse)  
5’-GGTACACTTTGTATTAAAGTCTGA 
G-3’ 
pepA1 forward  
 
5’-TACAGGTCGCCTATCTCTCA-3’ 
pepA1 reverse  
 
5’-CCACTGATGACTGGTGCTAT-3’ 
Bacteriocin forward  
 
5’-GGTGTTTGGAGCCATGGTAT-3’ 
Bacteriocin reverse  5’-TGTTTTGTTTCCACCCCAAG-3’ 
 
 
2.15.2. Generation of left and right flank overlap from pNZAK1 for cloning into pKFC 
pKFC plasmid DNA was routinely propagated through the use of chemically competent cells. 
Competent cells (30 µL) were thawed on ice for 10 min, before the addition of 1 µL of plasmid 
DNA (>30 ng/µL) (section 2.14.1). This mixture was incubated on ice for 10 min and heat 
shocked at 42˚C for 1 min, after which the cells were immediately cooled on ice for 1 min.  
After this, 500 µL of LB was added, and the cells were recovered at 37˚C with shaking for 30 
min. Cells (100 µL) were then plated onto LB agar containing 100 µg/mL ampicillin. The 
remaining cells from the initial 500 µL (400 µL) were plated on LB agar containing 100 µg/mL 
ampicillin. These plates were incubated at 37˚C overnight. To generate the left and right flanks 
from pNZAK1 homologous flanking regions (approximately 500 bp) adjacent (upstream and 
downstream) of the target gene were amplified by PCR. The PCR was done using primer pairs 
Bac1 and Bac2, and Bac3 and Bac4 for lactococcin 972, as well as primer pairs Pep1 and Pep2, 
and Pep3 and Pep4 for pepA1. The details for the PCR reaction and PCR cycles are shown in 
Table 2.6. After the PCR was completed, the samples were analysed by agarose gel 
electrophoresis and purified using the Zymo Gel DNA recovery kit. The purified DNA was 





To generate the left and right flank overlap, the upstream left and downstream right DNA flanks 
generated from PCR were fused together by overlap PCR in a two-step PCR procedure. This 
PCR involved primer pairs Bac2 and Bac3 for lactococcin 972, as we as Pep2 and Pep3 for 
pepA1. The flanks are homologous to pNZAK1 regions upstream and downstream of the target 
genes either pepA1 or lactococcin 972. The fused overlap is inserted in pKFC to carry out 
homologous recombination with pNZAK1.The PCR components and steps are shown in Table 
2.7.  
Table 2.6. Flank PCR reaction reagents and PCR method 
 
 
Components  Volume  
5´ Phusion HF buffer  10 µL 
dNTPs 10 mM 1 µL 
Forward primer (50 µM) 0.5 µL 
Reverse primer (50 µM)  0.5 µL 
DNA template (30 ng/µL)  0.5 µL 
Phusion Polymerase (2 U/µL)  0.5 µL 
MQ-H2O 37 µL 












Temperature (˚C)  Duration  
95  3 min  
95 




30s per kb   
72 10 min  













Figure 2.3. Diagram of pNZAK1 overlap fragment (left and right flank) sequence in the 
bacteriocin gene lactococcin 972 on pNZAK1. The red bar shows the left flank of the 
bacteriocin gene, the blue bar shows the right flank of the bacteriocin gene. The Bac2 and Bac3 
primers (Table 2.5) are shown as purple arrows with overlapping sequence in left and right 

















At the end of the first PCR 0.5 µL each of 50 µM primer (Bac3 and Bac2) was added to the 






Components  Volume   
5´ Phusion HF buffer  10 µL 
dNTPs 10 mM 1 µL 
Purified PCR product of each flank  1-2 pmol   
Phusion Polymerase (2 U/µL) 0.5 µL 
MQ-H2O 37 µL 
Total Volume 50 µL 
Temperature (C˚)  Duration  






30s per kb   
72 10 min  
12 Hold  
Temperature (C˚)  Duration  






30s per kb   
72 10 min  





After the overlap PCR was completed, the samples were run on a 1% agarose gel and gel 
extracted. The samples were recovered using the Zymo gel DNA recovery kit. The purified 
overlap fragment needs to be at least >20 ng/µL to be able to continue on to the next step.  
2.15.3. Restriction digest and ligation of pKFC and pNZAK1 flank overlap product 
generating pbac_pKFC and ppep_pKFC vectors  
Restriction digests of DNA were carried out in the enzyme buffer and conditions recommended 
by the manufacture. The shuttle vector pKFC and the finalised pNZAK1 flank overlap PCR 
products were digested with BamH1-HF (New England Biolabs). As required, digested vector 
DNA was treated with alkaline phosphatase (Roche) using 1 U of enzyme, according to the 
manufacturer’s instructions. The digested product was analysed by gel electrophoresis and 
purified using the Zymo Gel DNA recovery kit. The purified product was stored at -20˚C. The 
details of the components in the digest mixture are shown in Table 2.8. The purified and 
digested pKFC (vector) and insert DNA were ligated overnight at 16˚C using T4 DNA ligase 
(New England Biolabs). The components of the ligation mixture are shown in Table 2.9. The 
amount of overlap to use was calculated using the nebiocalculator.neb.com using a 1:3 molar 
ratio of vector:insert. Ligated products (pKFC-insert DNA) were transformed into E. coli 
MC1061 by heat shock for routine plasmid propagation. To alter the methylation state of the 
plasmid before transformation into S. aureus 14887 plasmid DNA was isolated and 










Table 2.9. Representative ligation reaction mixture 
 
 
2.15.4. Preparation of electrocompetent Staphylococcus aureus cells and transformation 
with pKFC 
An overnight culture (5 mL) of S. aureus in TSB was used to inoculate 50 mL of TSB to a 
starting OD600 of 0.1. Cells were grown to an OD600 of 0.6 to 0.8 and harvested by 
centrifugation at 3,000 × g at 4˚C for 10 min. The cell pellet was resuspended in 1 mL MQ-
H2O and centrifuged at 16,300 × g at 4˚C for 1 min. The supernatant was removed, and the 
MQ-H2O wash step was repeated three times. The washed cell pellet was resuspended in 1 mL 
sterile 10% (v/v) glycerol, and as before, the cell pellet was washed three times. The cell pellet 
was resuspended in 300 µL of 10% glycerol and the solution was aliquoted into three 
Eppendorfs each containing 70 µL of competent cells.  
Components  Volume / Concentration   
10´ CutSmart Buffer  5 µL  
DNA (plasmid or PCR product)  2-3 µg  
Restriction Enzyme (20 U/µL) 1 µL per µg of DNA  
Alkaline phosphatase (plasmid only)  1 µL (1U) per µg of DNA 
MQ-H2O  Up to 50 µL  
Components  Control  Plus insert  
10´ Ligation Buffer 2 µL 2 µL 
Plasmid (20 ng/µL) 1 µL 1 µL 
Insert  0 µL Variable Ratio  
Ligase (T4) (400 U/µL)   1 µL 1 µL  
MQ-dH2O  16 µL Up to 20 µL 
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Electrocompetent S. aureus cells were thawed on ice for 10 min before the addition of 1 µg of 
plasmid DNA. Cells were transferred to a pre-chilled 0.2 cm gapped electroporation cuvette 
(Biorad, USA), and were electrotransformed at 2300V, 25µF, 100W using a GenePulserTM 
(BioRad). Immediately after electroporation of the cells, 500 µL of TSB was added and the 
cells were allowed to recover by incubating at 28˚C for 2 h. Following this, 400 µL of cells 
were plated onto TSA containing chloramphenicol (10 µg/mL) and 200 µl of cells were plated 
TSA plates for each sample. Plates were incubated at 28˚C for 2 days.  
 
2.15.5. Temperature-dependent integration of ppep_pKFC and pbac_pKFC into host 
plasmid pNZAK1  
Overnight cultures (5 mL) of S. aureus 14487 transformed with plasmids pbac_pKFC and 
ppep_pKFC were grown in TSB containing chloramphenicol (10 µg/mL) and incubated 
overnight at 28˚C with shaking at 200 rpm. The following day, 1 mL of sterile TSB medium 
was aliquoted into three 1.5 mL Eppendorf tubes and heated to 43˚C (labelled 1/100, 1/1000 
and 1/10000). The overnight culture of the transformants was diluted 1/100 (e.g. 10 µL of 
culture to 990 µL of TSB), 1/1000 and 1/10000 into the appropriate Eppendorf tubes and then 
returned to 43˚C for 10 min. Following heating at 43 ˚C, 100 µl of each dilution was plated 
onto preheated TSA-chloramphenicol plates (10 µg/mL), and the plates were incubated at 43˚C 
in a plastic bag to prevent drying out. After 24 h the plates were examined for growth, if 
colonies were present, then PCR colony screening (see Table 2.4) was carried out to confirm 
integration. Two sets of primer pairs were used Bac5/Bac4 and Pep5/Pep4, as well as 
Bac6/Bac1 and Pep6/Pep1 (Table 2.5). Results were analysed by agarose gel electrophoresis. 
2.15.6. Excision of integrated vectors and generation of markerless deletion mutants 
A (5 mL) TSB universal was inoculated with an upstream integrant and another with a 
downstream integrant and incubated at 28˚C for 24 h (overnight culture one). Following this, 
10 µL of overnight culture was removed and sub-cultured into fresh (5 mL) TSB (Overnight 
culture two). Overnight culture one was then serially diluted 10-fold in TSB to 1´10-8 following 
this 50 µL aliquots of the 1´10-3 to 1´10-8 dilutions were spread plated onto TSA and incubated 
at 37˚C for 24 h. This passage step was repeated with the second overnight culture to generate 
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overnight culture three. Overnight culture two was serially diluted in the same way as overnight 
culture one.  
Colonies (100) from overnight culture one were patch plated onto TSA and TSA with 
chloramphenicol (10 µg/mL) and incubated overnight at 37˚C. The passage step was repeated 
with overnight culture three. The serial dilution step was also repeated with overnight culture 
three. Patch plate colonies were examined for loss of chloramphenicol resistance indicating 
excision of pKFC. Colonies that had reduced size or did not grow on the TSA chloramphenicol 
10 µg/mL plates were screened for pKFC excision using PCR. PCR primers used in the 
integration PCR were used again to screen for loss of ~5kb, this size of pKFC. A wild-type 
colony was included to show the expected product size after pKFC excision. PCR products 
were analysed by gel electrophoresis.  
When PCR screening identified potential colonies that could have lost pKFC and possibly the 
target gene, the colony was used to inoculate two (5 mL) TSB universals and incubated 
overnight. The overnight culture was the miniprepped to isolate the mutated pNZAK1 
following the protocol shown in section 2.14.1. A glycerol stock for the potential mutant was 
also generated and stored at -80˚C. The extracted pNZAK1 plasmid DNA was then nanodroped 
to check DNA quality and concentration and then stored at -20˚C. Plasmid DNA was sent to 
the Massey genome service for sequencing following their specifications for a sequencing 
reaction. The sequence was analysed via BLASTn to look for loss of pKFC DNA and target 
gene.  
2.16. Wild-type versus AK02 and AK03 screening for plasmid loss  
To investigate the loss of pNZAK1, relative to AK02 (∆pepA1) and AK03 (∆lactococcin 972) 
(Table 2.1), media-based assays were used. During the excision plating of pKFC, the loss of 
chloramphenicol resistance was found to coincide with the loss of ampicillin resistance.  
S. aureus 14487 isolates with pKFC integrated were serially passaged in TSB for 7 to 10 days 
at 37˚C at 200 rpm. Each day, 100 µL of overnight culture was used to inoculate a fresh 5 mL 
TSB universal. The serially passaged culture (100 µL) was diluted and plated at 1´10-5 to 
1´10 6 onto TSA and incubated overnight at 37˚C. Colonies (100) were then patch plated on to 
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TSA, TSA with chloramphenicol (10 µg/mL), and TSA with ampicillin (100 µg/mL) and 
incubated overnight at 37˚C. 
2.16.1. Plasmid loss assay  
Mutants AK02 and AK03, were streaked onto TSA with mupirocin (100 µg/mL) and grown 
overnight at 37˚C. From this a single colony was used to inoculate 5 mL ¼ MH containing 
mupirocin (100 µg/mL). The overnights of wild-type S. aureus 14487, AK02 and AK03 were 
used to inoculate (100 mL) ¼ MHB in a 250 mL flask to OD600 0.05 in technical duplicate and 
biological triplicate. A 50 µL sample of each flask was taken at the time of inoculation as day 
zero. The sample was serially diluted to 1´10-3 and 1´10-4 in PBS and 50 µL was plated onto 
¼ MHA plates and incubated overnight at 37˚C. Colonies (100) from each sample were patch 
plated onto ¼ MHA and ¼ MHA with ampicillin (100 µg/mL). The patch plates were then 
incubated overnight at 37˚C. The plasmid loss percentage was calculated based sensitivity to 
ampicillin. The serial dilution and patch plated steps were repeated on day three and day seven.  
2.17. Batch cultures pNZAK1 competition assay 
Wild-type S. aureus 14487 was tagged with rifampicin resistance through serial passaging in 
flat-bottom 96-well microtiter plates (ThermoFisher Scientific, New Zealand) at sub-MIC 
concentrations until a mutant was generated with rifampicin resistance (based on MIC/MBC 
values compared to wild-type). This isolate was used in the competition assay to differentiate 
wild-type S. aureus from ∆pNZAK1 S. aureus 14487.  
Wild-type S. aureus 14487 rifR and AK01 (see Table 2.1) were freshly streaked onto BHI agar, 
grown overnight and a single colony of each was used to inoculate two 5 mL BHI universals. 
The volume of culture needed of each strain to inoculate a 10 mL BHI universal to OD600 0.1 
(~1´108) was calculated. Then the volume of S. aureus 14487 pNZAK1- and Wild-type  
S. aureus 14487 rifR required to reach OD600 0.1 was added to an Eppendorf tube for each 
biological replicate. The Eppendorfs were then centrifuged at 16,300 ´ g and the supernatant 
was discarded. The pellet was washed in 1 mL PBS, and the wash step was repeated twice. The 
PBS was removed, and the cell pellet was resuspended in BHI in the same volume as previously 
calculated for the culture to reach OD600 0.1. The mixed culture of both WT rifR and AK01 
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strains was then used to inoculate a 10 mL BHI universal. Each biological replicate consisted 
of 3´10 mL BHI universals. A 50 µL sample was taken from each 10 mL universal and diluted 
to 1´10-3 and 1´10-4 and plated onto BHI agar and then incubated overnight at 37˚C. Colonies 
(100) were then picked and patched onto BHI agar, BHI agar with rifampicin (4 µg/mL) and 
BHI with ampicillin (100 µg/mL). The serial dilution steps and patch plating steps were 
repeated on day three and day seven. The results showed the percentage of RifR and AmpR cells 
in the mixed culture indicating the percentage of wild-type S. aureus 14487 and pNZAK1 










3. Introduction  
 
3.1. Plasmid maintenance overview 
 
Plasmids encode a variety of genes, a number of which under certain environmental stresses 
can provide the host cell with a selective advantage in these environments including, but not 
limited to resistance; to antibiotics, heavy metals, or even other bacteria (61). The presence of 
extrachromosomal DNA e.g. plasmid DNA can impose an ‘energetic limitation’ on the cells 
growth properties (growth rate), which in turn can impact plasmid stability (83). A plasmid is 
therefore generally only maintained long-term in the population (retained in daughter cells after 
cell division) if it encodes a gene that is beneficial to the bacterial host e.g. antibiotic resistance 
genes like blaZ or mupA in an environment under antibiotic selection.  
 
Studies have shown that energy limitation and nutrient deprivation can lead to increased MIC 
levels for bacteria to antibiotics like b-lactams (74). Additionally, small, slow-growing 
colonies can appear when bacteria are under energetic limitation, these slow-growing isolates 
are  termed small colony variants (SCV) (84). The slow-growing auxotrophic subpopulation of 
SCVs lead  to increased resistance levels to b-lactams and aminoglycosides from the decreased 
cell wall turnover and protein synthesis (84). Sigma factors, like SigB, can be activated by 
nutrient stress and cell envelope stress in S. aureus leading to increase resistance levels to b-
lactams and other antibiotics (74).  
 
Plasmids can also encode well characterised plasmid addiction mechanisms, and toxin-
antitoxin systems are one such example. These systems ensure that  only daughter cells, which 
inherit the plasmid survive. In brief, the plasmid encodes two closely linked genes, one which 
encodes a ‘toxin’, the other encodes the ‘antitoxin’ thus for the cell to survive it must maintain 
the plasmid. This system is exemplified by the bacteriocin toxin/antitoxin lactococcin 972 
system, which has been show to increase plasmid maintenance in Lactococcus lactis (Fig. 3.1) 
(67). In a study by Campelo et al.,  which, utilised four plasmids; pTRL1(a1) and pTRL1(b1) 
with lactococcin 972; and pTRL1(a2) and pTRL1(b2) without lactococcin 972. This study 


















Figure 3.1. pTRL1 plasmid maintenance with and without the lactococcin 972 bacteriocin 
gene cluster in Lactococcus lactis. The presence of lactococcin 972 on a plasmid can increase 
the plasmid maintenance over generations in comparison to plasmids that lack the bacteriocin 
gene. The figure was taken from the study by Campelo et al. (67). 
 
The plasmid pNZAK1 found in S. aureus 14487 is part of the PW2-like family of S. aureus 
plasmids found worldwide. These plasmids are known to carry antibiotic resistance genes such 
as mupA and blaZ as well as the suspected biocide tolerance gene qacA (60). pNZAK1 is a 
large plasmid at 27 kb and it is suggested to have a low copy number (personal communication 
by Dr. Glen Carter, Doherty institute, Melbourne, Australia.). Genomic analysis of pNZKA1 
revealed the presence of a presumptive lactococcin 972 bacteriocin cluster as well as a 
presumptive pepA1 toxin/anti toxin system. PepA1 is a type 1 toxin/antitoxin system which 
encodes SprA1AS antitoxin and SprA1 toxin, they are both encoded as antisense RNA (85). 
SprA1 is an antisense-RNA, which forms a cytotoxic peptide pepA1 that enters the plasmid 
membrane and forms a pour triggering cell death or death of competing bacteria (Fig. 3.2). 
SprA1AS is a cis-RNA that works to prevent host cell death through inhibiting a build-up of 






















Figure 3.2. pepA1 system (SprA1AS and SprA1) expression and mechanism. Summary 
diagram of SprA1AS and SprA1 gene locations and protein products and functions. SprA1 RNA 
inhibits the function of toxin RNA SprA1AS through binding. The SprA1 toxin RNA is able to 
express the peptide pepA1. Additionally, pepA1 interacts with the host cell membrane and 






3.1.1. Chemostat: A tool for investigating plasmid loss 
 
It was proposed that energy limitation in combination with the absence of antibiotic selection 
would create an environment that would induce plasmid loss of pNZAK1. To investigate the 
impact of energy limitation on plasmid loss this study used a chemostat, which is a unique tool 
for investigating energy limitation. The chemostat creates a continuous culture where the 
nutrient level, oxygen saturation and temperature are controlled. This allows precise control of 
the doubling time of the bacteria. This allowed S. aureus 14487 to be grown at 3, 10 and 30 
times slower than its normal growth rate in minimal media exerting an energy limitation on the 
bacteria.  
 
3.2. Hypothesis and research objectives  
 
Hypothesis 1: We hypothesised that the energy limited state of S. aureus NZ14487 cells grown 
at doubling times of 3 h, 10 h, and 30 h would impact the cells sensitivities to the encoded 
antimicrobial resistance determinants on plasmid pNZAK1. 
 
Hypothesis 2: We hypothesised that the energetic limitation imposed by continuous culture at 
slow growth rates would result in the loss of the plasmid pNZAK1 from S. aureus 14487. 
 
Hypothesis 3: Additionally, we hypothesised that the two plasmid addiction systems present 
on pNZAK1; the lacotcoccin 972 bacteriocin  (accession number: B0I1V8), and the pepA1 
system (accession number: 4B19_A), are involved in plasmid maintenance of pNZAK1 in 











Research Objective 1: To investigate the impact of energy limitation on antibiotic sensitivity, 
S. aureus NZ14487 was grown in continuous culture allowing steady state growth at fixed 
dilution rates of 0.231 h-1(3 h dt), 0.0693 h-1(10 h dt), and 0.023 h-1(30 h dt). 
 
Research Objective 2: To investigate the plasmid maintenance of pNZAK1 in S. aureus 
14487, cells were grown in a chemostat to create energy limiting conditions to stimulate 
plasmid loss. 
 
Research Objective 3: To understand the fitness cost of pNZAK1 in S. aureus 14487, a 
competition assay was carried out with wild-type S. aureus and AK01 ∆qacA mutant strain 
(see Table 2.1).  
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3.3. Investigating the effect of varied growth rates via batch and continuous culture on 
the antibiotic susceptibility profile of Staphylococcus aureus 14487 
 
3.3.1. S. aureus 14487 growth properties in batch culture 
 
To investigate the growth properties of S. aureus 14487, which harbours the plasmid pNZAK1, 
cells were grown in batch culture with shaking in the absence of any antibiotic or antiseptic 
treatment (Fig. 3.3). When S. aureus  was grown in a standard 250 mL flask containing 100 
mL of ¼ strength MHB, the organism reached an OD600 of approximately 1.0, after ~5 h at 
37°C in batch. Under these conditions, S. aureus 14487 had a doubling time of 1.64 h, equating 
to a specific growth rate of 0.421 h-1, and typically reached a maximum OD600 of 1.8 (after 24 
h). When S. aureus was grown in TSB it had a doubling time of 0.830 h , equating to a specific 
growth rate of 0.834  h-1 and reached a maximum OD600 of 11 (after 24 h).  
 
3.3.2. S. aureus 14487 growth properties in continuous culture via a chemostat  
 
To examine the growth properties of S. aureus 14487 under general energy limited continuous 
culture conditions a chemostat was utilised. As the MHB broth used in this experiment is not 
a true minimal medium the concentration was decreased to ¼ strength in order to impose an 
energy restriction from general nutrient limitation on the S. aureus cells. The chemostat 
peristaltic media pump was turned on and controlled to facilitate cell dilution rates of 0.231  
h-1 (3 h dt), 0.0693 h-1 (10 h dt), and 0.023 h-1 (30 h dt). The dilution rate, temperature of 37˚C, 
oxygen saturation (50%), and nutrient level were precisely controlled. Samples for analysis 
were removed once the cells had reached steady state. The steady state OD600 for the 3 h 
doubling time was typically around 0.9, whereas for the 10 h and 30 h doubling time the steady 
state OD600 were 1.4, and 1.5 respectively (Fig. 3.4A-B). Steady state was reached after 3-4´ 











Figure 3.3. Growth of S. aureus 14487 in batch culture. Cells of S. aureus 14487 were 
inoculated to an initial OD600 of 0.05 and were grown in ¼ strength MHB (black circle) and 
TSB (grey square). Growth was monitored by the change in optical density (OD600). Under 
these conditions, S. aureus 14487 had a doubling time of 1.64 h in ¼ MHB , equating to a 
specific growth rate of 0.421 h-1. S. aureus 14487 had a doubling time of 0.830 h in TSB, 
equating to a specific growth rate of 0.834 h-1. The rate was calculated from the 1h to 4 h OD600 
points at the exponential phase. 














































Figure 3.4. Growth of S. aureus 14487 in continuous culture. S. aureus 14487 cells were 
inoculated to an initial OD600 of 0.05 and were grown in ¼ strength MHB. Growth was 
monitored by the change in OD600. Red arrows indicate the time points at which samples were 
withdrawn for MIC, MBC, and plasmid loss assays for the following conditions; 3 h doubling 
time (0.231 h-1) ( ),10 h doubling time (0.0693 h-1) ( ), and 30 h doubling time (0.023  
h-1) ( ).  
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3.3.3. The antimicrobial sensitivity of S. aureus 14487 is not significantly impacted by the 
cellular growth rate 
 
To investigate the effect that decreasing growth rates had on the antibiotic susceptibility profile 
of S. aureus 14487, the organism was grown in a continuous culture system, which allowed 
precise control of the conditions in which the bacteria were grown. The cells were grown at 
dilution rate of 0.231 h-1 (3 h dt), 0.0693 h-1 (10 h dt) and 0.023 h-1 (30 h dt). To investigate if 
the antimicrobial sensitivity of S. aureus 14487 towards mupirocin, fusidic acid, ampicillin, 
and chlorhexidine was influenced by the cellular growth rate, we determined the MIC and 
MBC for each given growth rate (Table 3.1). The MIC and MBC assays were carried out in 
technical triplicates and biological duplicates.  
 







3 h Mupirocin 128-256 256 
 Fusidic Acid 16 128 
 Ampicillin 32 128 
 Chlorhexidine 2 2-4 
10 h Mupirocin 256 >256 
 Fusidic Acid 16 256 
 Ampicillin 64 128 
 Chlorhexidine 2 2-4 
30 h Mupirocin 256 >256 
 Fusidic Acid 16-32 128-256 
 Ampicillin 32 64-128 
 Chlorhexidine 2 2-4 
aMIC, minimum inhibitory concentration for each test compound, bMBC, minimum 
bactericidal concentration for each test compound. Data is representative of biological 




When S. aureus 14487 was grown at a 3 h doubling time, the MIC for mupirocin (mupA on 
pNZAK1) was between 128 and 256 µg/mL and remained unchanged when the doubling time 
was decreased to 10 h, and then 30 h. The MIC for fusidic acid was determined to be 16 µg/mL 
for the 3 h and 10 h doubling times, but it increased 2-fold to 32 µg/mL when the cells were 
grown at a 30 h doubling time. The sensitivity of ampicillin increased 2-fold between the 3 h 
and 10 h doubling time, from 32 µg/mL to 64 µg/mL, however, the MIC reverted to 32 µg/mL 
when the cells were grown at a 30 h doubling time. The MIC of chlorhexidine did not appear 
to be affected by the growth rate, and the MIC remained at 2 µg/mL.  
 
As MIC assays only measure the inhibition of bacteria by the compound and not the killing of 
the bacteria, MBC assays were used to investigate the bactericidal activity of each compound 
at the three growth rates. The MBC for mupirocin was 256 µg/mL when the S. aureus cells 
were grown at a 3 h doubling time and increased beyond 256 µg/mL for both the 10 h and 30 
h doubling times. S. aureus 14487 had a stable MBC of 128 µg/ml for ampicillin for the 3 h 
and 10 h doubling times. The 30 h MBC for ampicillin was between 64 and 128 µg/mL. The 
MBC for fusidic acid was determined to be 128 µg/mL for both the 3 h and 10 h doubling 
times, increasing to 128 to 256 µg/mL for the 30 h doubling time. Like the results from the 
MIC assay for chlorhexidine, the MBC also did not appear to change and stayed constant at  
 µg/mL for all growth rates examined. To confirm that any changes in MIC and MBC values 
were not influenced by the ratio  of viable cells to antibiotic we confirmed that there was no 
significant change in the cell numbers for each given growth rate by determining the CFU/mL. 
Overall, the MIC and MBC values for mupirocin, fusidic acid, appeared to increase albeit by 
one antibiotic dilution as the growth rate decreased, specifically when grown at a 10 h doubling 
time. The ampicillin MIC and MBC appeared to decrease between the 10 h and 30 h point. 








3.4. Stability of the plasmid pNZAK1 under energy limitation imposed by continuous 
culture  
 
To investigate if the energy limitation imposed by growth rates up to 30´ slower than batch 
growth impacted the maintenance of plasmid pNZAK1 within the population, we utilised 
continuous culture in a chemostat. Cultures were grown as previously described (see Section 
2.6), and samples were removed at the time points indicated in Fig. 3.4. Plasmid stability assays 
were conducted by patch plating 100 colonies onto MHA with or without ampicillin (6 µg/mL) 
and BHI agar. We examined 300 colonies from each growth rate in biological duplicate (Table 
3.2). Colonies where no growth was observed on ampicillin were recorded as isolates which 
had lost the plasmid pNZAK1, as resistance to ampicillin is encoded on the plasmid only.  
 
Table 3.2. Stability of pNZAK1 plasmid from S. aureus 14487 under different growth rates 












a CFU/mL, colony forming units per millilitre. Data is representative of biological duplicates.    
 
From the plasmid stability assays shown in Table 3.2 we observed that for the 3 h doubling 
time the plasmid loss was 5.4% and 1% from two biological replicates. The 10 h doubling time 
samples maintained a 1.7% and 1.4% plasmid loss from 300 patch plated colonies. There was 
6% and 1.7% plasmid loss from the samples taken from the 30 h doubling time. These data 
showed that the pNZAK1 plasmid is stable and maintained in the chemostat cell population in 
Doubling Time pNZAK1 loss (%) CFU/mLa of 
Chemostat sample 
used for plasmid loss 
assay 
3 h  284/300 (5.4%) 3.8x108 
 296/300 (1%)  
10 h 295/300 (1.7%) 2.4x108 
 296/300 (1.4%)  
30 h 282/300 (6%) 4.4x108 
 295/300 (1.7%)  
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S. aureus 14487 despite the energy limitation of growing at a doubling time 30´ slower than 
that of batch growth and without antibiotic selection. With the exception of experimental 
variability between biological replicates, decreasing the doubling time of S. aureus 14487 cells 
from 3 h, to 30 h did not have a significant impact on plasmid stability/loss. These data indicate 
that a proportion of daughter cells within the chemostat culture naturally appeared to have lost 
the plasmid pNZAK1, independent of any imposed energy limitation. Furthermore, it also 
indicates that losing the plasmid pNZAK1 provides no additional growth advantage, as these 
cells failed to accumulate and out compete cells still harbouring pNZAK1 within the chemostat. 
Interestingly, this small proportion of cells without pNZAK1 is maintained despite the presence 
of two plasmid addiction systems, see section 3.6 for further information. 
 
3.4.1. Plasmid loss isolates drug sensitivity profile 
 
While it was demonstrated that the plasmid pNZAK1 was highly stable in the majority of cells 
recovered from the chemostat at decreasing growth rates, we were able to isolate a population 
of cells that had presumptively lost the plasmid, as determined by patch plating (Table 3.2). To 
confirm that these results were due to plasmid loss rather than a mutation (inactivation) in the 
gene conferring resistance, for example to ampicillin (blaZ), these presumptive isolates were 
tested to determine if they had altered MIC’s for mupirocin, fusidic acid, ampicillin, and 















Table 3.3. Antibiotic sensitivity of plasmid loss isolates as measured by the MIC to selected 
antimicrobials 
aIsolates identified from plasmid stability experiments which displayed changes in MIC compared to 
the wild type S. aureus 14487. b MIC, minimum inhibitory concentration for each test compound was 
determined by lack of growth in well. This data is representative of technical triplicate and biological 
duplicates.  
Doubling Time Plasmid Loss 
Isolates a 
  
MIC (µg/mL) b 
 
  Mupirocin Fusidic Acid Ampicillin Chlorhexidine 
Wild-Type  
S. aureus 14487 
  128-256   16 32-64            2 
3 h 3-2-44  0.5 8 0.5 1 
 3-2-162  0.125 8 0.5 1 
10 h 10-1-189  0.125 8 0.5 1 
 10-1-233  0.25 8 0.5 1 
 10-1-234  0.125 8 0.5 1 
 10-1-250 0.5 8 1 1 
 10-2-186 0.5 8 0.25 1 
30 h 30-1-37 0.25 8 0.5 1 
 30-1-38 0.125 8 0.5 1 
 30-1-113 0.125 8 1 1 
 30-1-157 0.125 8 0.5 1 
 30-1-206 0.25 8 0.5 1 
 30-2-103 0.25 8 2 1 
 30-2-124 0.25 8 2 1 
 30-2-167 0.5 4 2 2 
 30-2-176 0.5 8 1 1 
 30-2-212 1 16 4 2 
 30-2-231 0.25 8 1 4 
 30-2-232 0.5 8 2 1 
 30-2-276 0.25 8 1 2 
 30-2-296 0.25 4 1 1 
 
 69 
The results indicated that the isolates that lost the plasmid showed an overall decrease in MIC 
(increased susceptibility) for all tested compounds. The MIC for mupirocin in some isolates 
decreased 2048-fold from 256 µg/mL to 0.125 µg/mL - 1 µg/mL. MIC values for fusidic acid 
decreased to 8 µg/mL, where two 30 h isolates had an MIC of 4 µg/mL and one 30 h isolate 
having and MIC of 16 µg/mL. For all the growth rate isolates collected the MIC for ampicillin 
decreased at least 16-fold to be between 0.25 µg/mL - 2 µg/mL. The MIC for chlorhexidine 
was predominantly 1 µg/mL with three isolates at 2 µg/mL and one at 4 µg/mL. These results 
show that there was a dramatic increase in antibiotic sensitivity for the isolates that had 
presumptively lost the plasmid pNZAK1 compared to the parental S. aureus 14487 isolate.  
 
3.4.2. Genomic analysis of plasmid loss isolates  
 
To identify any significant mutations which may have occurred due to growth up to 30´ slower 
than batch, selected isolated which had presumptively lost the plasmid were analysed by whole 





















Table 3.4. Chromosomal sequencing analysis of plasmid loss isolates 
Doubling 
time 
Isolates Whole genome sequencing results  
3 h 3-2-44  1. ACG	àà AGG, Threonine to Arginine at amino acid 1,210 of 
a ‘DUF1542 containing-protein’ (similar to FmtB or SasC)  3-2-162  
10 h 10-1-189  1. ACG	àà AGG, Threonine to Arginine at amino acid 1,210 of 
a ‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
 10-1-233  1. ACG	àà AGG, Threonine to Arginine at amino acid 1,210 of 
a ‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
2. TTA	àà TCA, Leucine to Serine at amino acid 83 of an 
adenine phosphoribosyltransferase  
 10-1-234  1. ACG	àà AGG, Threonine to Arginine at amino acid 1,210 of 
a ‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
2. Frameshift in a DNA-binding response regulator, with +TG 
following amino acid 129 of the normally 220 amino acid protein  
 10-1-250 1. ACG	àà AGG, Threonine to Arginine at amino acid 1,210 of 
a ‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
2. GGA	àà AGA, Glycine to Arginine at amino acid 209 of 
YSIRK signal domain/LPXTG anchor domain surface protein 
3. AAA	àà GAA, Lysine to Glutamic Acid at amino acid 82 of 
an adenine phosphoribosyltransferase, the same gene as in 
DMG1701341  
4. CAT	àà CGT, Histidine to Arginine at amino acid 220 of an 
ATP-binding protein  
 10-2-186 1. ACG	àà AGG, Threonine to Arginine at amino acid 1,210 of 
a ‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
2. GGA	àà AGA, Glycine to Arginine at amino acid 209 of 
YSIRK signal domain/LPXTG anchor domain surface protein 
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3. AAA	àà GAA, Lysine to Glutamic Acid at amino acid 82 of 
an adenine phosphoribosyltransferase, the same gene as in 
DMG1701341  
4. CAT	àà CGT, Histidine to Arginine at amino acid 220 of an 
ATP-binding protein  
30 h 30-1-37 1. ACG à AGG, Threonine to Arginine at amino acid 1,210 of a 
‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
2. TCAàTTA, Serine to Leucine at amino acid 213 of the 
transcriptional regulator of the lactose metabolism operon lacA-lacG  
3. Deletion of 22 genes including:  
§ A cation transporter 
§ An aldehyde dehydrogenase 
§ A bifunctional acetaldehyde-CoA/alcohol dehydrogenase  
§ Six genes involved in capsular biosynthesis  
4. AAA à GAA, Lysine to Glutamic Acid at amino acid 82 of an 
adenine phosphoribosyltransferase,  
5. AAG à AAT, Lysine to Asparagine at amino acid 302 of a 
hydroxyacid dehydrogenase  
6. TTTàTCT, Phenylalanine to Serine at amino acid 182 of a DNA-
binding response regulator, immediately downstream from the ATP-
binding protein that was mutated in 10 h isolates 
 30-2-296 1. ACG à AGG, Threonine to Arginine at amino acid 1,210 of a 
‘DUF1542 containing-protein’ (similar to FmtB or SasC) 
2. TCAàTTA, Serine to Leucine at amino acid 213 of the 
transcriptional regulator of the lactose metabolism operon lacA-lacG  
3. Deletion of 22 genes including:  
§ A cation transporter 














Through whole genome sequencing we confirmed that plasmid loss isolates all lost the 
pNZAK1 plasmid (Table 3.4). The 3 h isolates, 3-2-44 and 3-2-162 both had mutations in the 
DUF1542 protein that is similar to FmtB, which encodes methicillin resistance and SasC and 
is associated with biofilm formation, and cell aggregation (86,87). 10 h isolates all showed the 
same mutation in DUF1542 as the early isolates. Isolates 10-1-233, 10-1-250, and 10-2-186 all 
had mutations leading to an amino acid change in adenine phosphoribosyltransferase, which 
aids in the uptake of adenine, a vital purine needed for DNA replication (88). Isolate 10-1-234 
had frameshift in a DNA response regulator leading to a truncated polypeptide. DNA response 
regulators help bacteria respond to generalised nutrient limitations and other environmental 
stresses (89). Isolates 10-1-250 and 10-2-186 also had an amino acid change in the YSIRK 
signal domain/LPXTG anchor domain surface protein which is involved in many surface 
proteins e.g. protein A (90). Isolates 10-1-250 and 10-2-186 showed an amino acid change in 
an ATP-binding protein. The end-point isolates from the 30 h doubling time both shared the 
DUF1542 mutation, the alteration in adenine phosphoribosyltransferase as well as a mutation 
in the DNA response regulator of an ATP-binding protein. Additionally, these isolates had a 
mutation in the transcription regulator of the lacA-lacG operon which is involved in the 
utilisation of lactose and galactose (91). Both isolates had 22 gene deletions which included a 
cation transporter, an aldehyde dehydrogenase, an acetaldehyde-CoA/alcohol dehydrogenase 
and 6 capsular biosynthesis genes (92).  
 
 
§ A bifunctional acetaldehyde-CoA/alcohol dehydrogenase  
§ Six genes involved in capsular biosynthesis  
4. AAA à GAA, Lysine to Glutamic Acid at amino acid 82 of an 
adenine phosphoribosyltransferase  
5. CAG à TAG, Glutamine to STOP at amino acid 67 of a two-
component sensor histidine kinase  
6. TTTàTCT, Phenylalanine to Serine at amino acid 182 of a DNA-
binding response regulator, immediately downstream from the ATP-




These deletions could significantly hinder the metabolism of the bacteria as well as decrease 
the virulence with the loss of capsular biosynthesis genes. Overall, the isolates taken at the 3 h 
doubling time had less phenotypically significant mutations compared to those isolates taken 
from the 30 h doubling time. These gene deletions were thought to be potentially 
phenotypically important, but it is uncertain if they play a role in plasmid maintenance.  
 
3.5. pNZAK1 competition assay: Wild-type Staphylococcus aureus 14487 versus AK01 
pNZAK1- strain    
 
To investigate the fitness cost of harbouring pNZAK1, we compare the survival of wild-type 
cells to that of isolates which have lost the plasmid pNZAK1- (Fig. 3.5). For this experiment, 
we selected the isolate 3-2-162 from the 3 hour doubling time, and designated this isolate AK01 
pNZAK1- (Table 2.1). In order to differentiate the two isolates from each other, we tagged the 
wild-type S. aureus 14487 with rifampicin resistance, generating the strain S. aureus 14487 
rifR. The ratio of wild-type S. aureus to AK01 pNZAK1- strain was measured using rifampicin 






















Figure 3.5. Competition assay showing the proportion of wild-type S. aureus 14487 rifR 
in the presence of AK01 pNZAK1- following non-selective growth. Wild-type S. aureus 
14487 rifR and AK01 pNZAK1- cells were grown in BHI over 7 days at 37˚C with shaking at 
200 rpm. Wild-type S. aureus 14487 were tagged with rifampicin resistance (rifR). Day 1 
sample was taken 24 h after inoculation. At the indicated times samples were withdrawn, plated 
on BHI agar, and then patch plated onto BHI agar, BHI agar with rifampicin (4 µg/mL), and 
BHI agar with ampicillin (100 µg/mL) to calculate the percentage of wild-type S. aureus 14487 
in a mixed culture. Data represents the results of 3 independent experiments, with error bars 




Given the lack of fitness cost imparted on the cells by pNZAK1 when grown in continuous 
culture we investigated the effect of the pNZAK1+/pNZAK1-  phenotype in competition 
experimets. To facilitate this experiment, we generated a wild-type rifampicin resistant strain 
(rifR) by serial passaging. We confirmed that this mutant had no observable fitness cost through 























Figure 3.6. Growth of S. aureus 14487 in batch culture in BHI. Cells of wild-type (black 
triangle), rifR strain (grey square) and AK01 (grey circle) were inoculated to an initial OD600 
of 0.05 and were grown in BHI Growth was monitored by the change in optical density (OD600). 
Under these conditions, all S. aureus 14487 strains had a doubling time of 0.7264 h in BHI, 























equating to a specific growth rate of 0.954 h-1. The rate was calculated from the 1h to 4 h OD600 
points at the exponential phase.  
Our results showed that on Day 1 (24 h after inoculation) there was approximately 60% wild-
type S. aureus 14487 present in the mixed culture, and approximately 40% AK01 pNZAK1-. 
By Day 3 the percentage of wild-type S. aureus 14487 decreases to approximately 50%. 
However, by Day 7 the proportion of wild-type S. aureus 14487 decreased to approximately 
15%. These data indicate that either pNZAK1 imposes a fitness cost on  
S. aureus 14487, as the wild-type strain can be outcompeted in batch culture in the absence of 
selective pressure, or that a plasmid addiction system is expressed. This system could kill wild-
type cells over the course of the experiment while the plasmid-loss isolate has already mutated 
to be able to survive in the presence of the toxin. These data also suggest that under the 
experimental conditions reported, there was no observable transfer of pNZAK1 into the cured 
strains, given the proportion of cells observed (pers. comm. Dr Glen Carter, Doherty Institute, 
Melbourne).  
 
3.6. Identification of plasmid addiction systems in pNZAK1 
 
The maintenance of pNZAK1 in S. aureus cells is stable in the absence of antibiotic selective 
pressure (Table 3.2), stable under energy limiting conditions, and pNZAK1+ cells are 
outcompeted by pNZAK1- in rich media at stationary phase (Fig. 3.5). These data suggest that 

























Figure 3.7. Analysis of putative bacteriocin gene, lactococcin 972, in pNZAK1. 
 (A) The BLASTp comparison of the query pNZAK1 amino acid sequence compared to the 
lactococcin 972 bacteriocin sequence. (B) The gene cluster of the lactococcin 972 bacteriocin, 





























Figure 3.8. Amino acid sequence of pepA1 and BLASTn search.  
(A) The amino acid sequence of pepA1 from pNZAK1 taken from the program Geneious.  
(B) The BLASTn search of the amino acid sequence highlighting pepA1 as a potential match 


















Previously, pMW2-like plasmids have been shown to have genes encoding a putative 
bacteriocin, and analysis of pNZAK1 indicate that the putative bacteriocin is lactococcin 972 
(Fig. 3.7) (60). Our analysis also revealed that pNZAK1 putatively encode pepA1, a type 1 
antitoxin system (Fig. 3.8). 
 
3.7. Development of PCR products to generate markerless deletion mutants in the 
plasmid pNZAK1 by homologous recombination  
 
As described, two presumptive plasmid addiction systems, lactococcin 972 and pepA1, were 
identified to be encoded on pNZAK1 and were hypothesised to be involved in the maintenance 
of pNZAK1. To investigate the role of these two plasmid addiction systems, we therefore 
undertook experiments to individually delete the lactococcin 972 system, and the pepA1 
toxin/antitoxin system. The knockouts were generated via markerless gene deletion  method as 
























Figure 3.9. Schematic representation of markerless deletion of target genes (lactococcin 
972 and pepA1) in pNZAK1 mediated by the shuttle vector pKFC. To selectively target a 
gene for deletion in pNZAK1 e.g. lactococcin 972, two homologous fragments upstream and 
downstream of the target gene were amplified using the primer pairs Bac1/Bac2 and Bac3/4 
(Table 2.5). These homologous DNA flanks were fused together by PCR overlap extension 
using primer pair Bac2/Bac3. The fused overlaps for both lactococcin 972 and pepA1 were 
separately cloned into pKFC generating the markerlesss deletion vectors; ppep_pKFC and 






Figure 3.10. Representative diagram of left and right flanks of lactococcin 972 and pepA1 
primers and fragment size on pNZAK1. (A) lactococcin 972 left flank of 570 bp with Bac1 
and Bac2 primers and right flank of 583 bp with Bac3 and Bac4 primers. (B) pepA1 left flank 
of 628 bp with Pep1 and Pep2 primers and right flank of 578 bp with Pep3 and Pep4 primers. 
These fragments were generated from pNZAK1. 
 
The first step in the deletion process was to generate by PCR homologous flank regions 
(approximately 500-600 bp) just upstream and downstream of the target genes amplified from 
pNZAK1 (lactococcin 972 or pepA1) (Fig. 3.10). For each gene the primer pair Bac1/Pep1 and 
Bac2/Pep2 were used to generate the left flank and to create the right flank primer pair 
Bac3/Pep3 and Bac4/Pep4 were used. The generated PCR pairs; lactococcin 972 Left and Right 
and pepA1 Left and Right flanks (Fig. 3.11 A ) were then fused together through a two-step 



























Figure 3.11. Generation of flanking regions and flank overlaps by PCR to facilitate the 
markerless deletion of lactococcin 972 and pepA1. Lane 1 (from left) contains the DNA 
Ladder GeneRuler 1 kb. (A) Generation of the lactococcin 972 bacteriocin left (Lane 2-3) and 
right flanks (Lane 4-5), and generation of the pepA1 left (Lane 6-7)  and right flanks (Lane 8-
9) by PCR. (B) Generation of the flank overlap PCR products from the lactococcin 972 
bacteriocin flanks, PCR product is indicated by the red arrow (1153 bp) in 8 replicates (Lane 
1-8) from (A lane 2-5). (C) Generation of the flank overlap PCR from the pepA1 flanks (from 
(A lane 6-9 )). The PCR product is indicated by the red arrow (1206 bp) in 4 replicates (Lane 
1-4) and gel purified.  
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After the overlap PCR products for each gene were generated, the overlap  product was cloned 
into the pKFC vector (see section 2.15.7-8) and maintained on agar containing 
chloramphenicol (10 µg/mL), thereby generating modified shuttle vectors ppep_pKFC and 
pbac_pKFC (Table 2.1). 
 
3.7.1. Integration screening for temperature dependent allelic replacement via double-
crossover recombination 
 
After the modified pKFC vectors were transformed into S. aureus 14487, the cultures were 
heated to 43˚C to induce integration of the plasmids ppep_pKFC and pbac_pKFC into plasmid 
pNZAK1. This temperature is non-permissive for plasmid replication, but the isolate retains 
chloramphenicol resistance. Colonies that grew on agar plates with chloramphenicol (100 
µg/ml) at 43˚C were screened for pKFC integration through PCR, using primers pairs 
Bac5/Bac2 and Pep5/Pep2 for the upstream integration screen and primers pairs Bac3/Bac4 
and Pep3/Pep4 for the downstream integration screen. PCR products were analysed by agarose 

























Figure 3.12. PCR validation of pKFC (ppep_pKFC and pbac_pKFC) integration into 
pNZAK1 within S. aureus 14487. (A) The pepA1 presumptive integrants were verified by 
PCR using primers Pep5/2 (L) and Pep3/6 (R) from chloramphenicol-resistant colonies (10 
µg/mL). (B) The lactococcin 972 putative integrants were verified by PCR using primers 
Bac5/Bac2 (L) and Bac3/Bac6 (R) from chloramphenicol-resistant colonies (10 µg/mL). Lane 
1 (from left) contains the DNA Ladder GeneRuler 1 kb. Lanes 1-8 (as indicated on agarose gel 








Screening revealed that lane 1- 5 in Fig. 3.12A were potential pepA1 pKFC integration isolates 
as the product size varied from the expected wild-type S. aureus size of 1.7 kb left product and 
1.5 kb right product. Putative integrants from lane 2 and 6 were sequenced. 
 
Lane 1, 7, and 8 in Fig. 3.12B were possible lactococcin 972 bacteriocin integration isolates as 
the product size varied from the expected 1.7 kb left and right wild-type flank size. Putative 
integrants from lane 1 and 8 were sequenced.  
 
To confirm that the presumptive integration isolates were correct, we sequenced using primers 
Bac5/Pep5 and Bac2/Pep2 for the upstream integration screen and primers Bac3/Pep3 and 
Bac4/Pep4 for the downstream integration screen. The sequencing results found one pepA1 
pKFC integration isolates and two lactococcin 972 bacteriocin integration isolates. 
 
3.7.2. Excision of plasmid ppep_pKFC or pbac_pKFC in pNZAK1 by double-crossover  
 
As DNA sequencing indicated that we had successfully integrated one ppep_pKFC and two 
pbac_pKFC,we proceeded with excision plating to excise the integrated ppep_pKFC  or 
pbac_pKFC from pNZAK1 through a double crossover recombination event. The integration 
ppep_pKFC isolate and two pbac_pKFC integration isolates were grown on TSA at 28˚C and 
serially passaged into TSB broths without chloramphenicol selective pressure. After each 
passage the colonies were plated onto TSA with and without chloramphenicol. Colonies that 
were found to be sensitive to chloramphenicol were screened for pKFC excision using PCR 
with Bac5/Bac6 or Pep5/Pep6 primers. The PCR products were then analysed by agarose gel 

































Figure 3.13. PCR validation of excision screening of ppep_pKFC or pbac_pKFC from 
pNZAK1 in S. aureus 14487. (A) ppep_pKFC excision screening of sequence confirmed 
integration isolate, replicates in lanes 1-8 (from left) with Pep5/Pep6 integration primer pair. 
(B) sequence confirmed pbac_pKFC integration isolate one excision screening of pbac_pKFC 
with Bac5/Bac6 integration primer pair, (replicates in lanes 1-10) as indicated on agarose gel 
image. (C) DNA sequence confirmed pbac_pKFC integration isolate 2 excision screening with 
Bac5/Bac6 integration primer pair (replicates in lane 1-10). Wild-type control shown in lane 
11 in all agarose gels (lactococcin 972; 2373 bp, pepA1; 1878 bp). The ladder used was 
GeneRuler 1 kb ladder. The red arrow indicates the expected product.   
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The excision screening identified two presumptive isolates; AK02 (Fig. 3.13A, lane 1) and 
AK02.1 (Fig. 3.13A, lane 6), which appeared to have excised pKFC resulting in the deletion 
of the pepA1 gene. Likewise, we were able to isolate AK03 (Fig. 3.13B, lane 1) which appeared 
to have excised pKFC resulting in the deletion of the lactococcin 972 gene. To confirm the 
presumptive mutants, plasmid DNA was isolated, and analysed by DNA sequencing using 
integration primers pairs Bac5/Bac6 and Pep5/Pep6. The expected deletion sizes shown in 
Table 3.5. 
 
Table 3.5. Markerless deletion genes and related fragment sizes in modified pKFC vector 
 
 
3.7.3. Gene deletion screening  
 
To further validate the presumptive mutants; AK02, AK02.1, and AK03 then isolates were 
sequenced using integration primers Pep5 and Pep6 for pepA1 (Fig. 3.14A), and integration  
primers Bac5 and Bac5 for lactococcin 972 (Fig. 3.14B). Samples were analysed by agarose 






















bacteriocin   
318 570 583 1153 




























Figure 3.14. PCR validation of deletion of pepA1 or lactococcin 972 from pNZAK1 in           
S. aureus 14487. (A) PCR product of AK02 (1728 bp) and AK02.1 with Pep5/Pep6 integration 
primers with wild-type control (1878 bp). (B) PCR product of AK03 (2055 bp) with Bac5/Bac6 
integration primer with wild-type control (2373 bp). The ladder used was GeneRuler 1 kb 
ladder. Red arrows indicated expected wild-type size. AK02.1 was shown to have not 




Analysis by agarose gel electrophoresis revealed a 150 bp deletion for the pepA1 mutant, AK02 
(Fig. 3.14A), and a 318 bp deletion for the lactococcin 972 bacteriocin isolate, AK03 (Fig. 
3.14B) (Table 2.1). Taken with the DNA sequencing data we had successfully introduced the 
two independent single deletions of pepA1 and lactococcin 972 bacteriocin in the plasmid 
pNZAK1. No attempts in this study were made to generate a double mutant isolate, lacking 
both pepA1 and lactococcin 972 bacteriocin. To ensure that no secondary mutations had 
occurred in this process, which may impact our analysis, we sent the two isolates for whole 
genome sequencing.  
 
3.8. Characterisation of mutants S. aureus AK02 and AK03 
 
3.8.1. Excision plating: chloramphenicol and ampicillin screening  
 
As part of the process to generate the two mutants we periodically observed that the loss of 
chloramphenicol resistance (CmS) (indicating loss of pKFC) coincided with the loss of 
ampicillin resistance (AmpS), which is encoded only on pNZAK1. This data suggested that the 
excision of pKFC and potential generation of a deletion mutant might stimulate the loss of 
pNZAK1 from S. aureus 14487. To investigate this observation further we went back to the 
serially passaged excision patch plates containing colonies with the integrated plasmids; 
ppep_pKFC and pbac_pKFC, and transferred Cms colonies (that have lost pKFC) from TSA 
plates onto TSA plates containing ampicillin (100 µg/mL) (Fig. 3.15). Of the colonies which 
were CmS indicating loss of pKFC, 30-40% were also observed to be AmpS for AK03 whereas 
10- 20% of the CmS AK02 were AmpS . This was the first instance where we had observed a 







Figure 3.15. Ampicillin sensitivity of integration colonies, AK03 and AK02, that have 
excised pKFC. Integration colonies that were shown to have lost pKFC (CmS) were patch 
plated on to TSA supplemented with ampicillin (100 µg/mL ) to look for loss of pNZAK1. The 
frequencies of CmS S. aureus colonies also being AmpS is shown above for both the AK03 
isolate (∆bac) and the AK02 isolate (∆pepA1).   
 
3.8.2. Investigating the plasmid stability of the pNZAK1 mutants AK02 and AK03  
 
To investigate plasmid loss of pNZAK1 in the AK02 and AK03 mutants the strains were grown 
in ¼ strength MH medium to limit nutrients in 100 mL volumes in flasks.  
 
The plasmid loss assays in ¼ MH flasks shown in Table 3.6 showed that pNZAK1 is stable in 
S. aureus 14487 and that the single deletions of either plasmid addiction systems, pepA1 or 
lactococcin 972 results in marginally increased levels of plasmid loss of 1.75% and 2.25% 
respectively, up from 0.5%. These data suggest that the pepA1 system and lactococcin 972 
bacteriocin may not be involved in the maintenance of pNZAK1 in S. aureus 14487, or that in 
the single mutants we have generated here, the presence of one system is sufficient to maintain 



















































                 




Strains  Day 0 average 
plasmid loss 
(%) 
Day 3 average 
plasmid loss 
(%) 
Day 7 average 
plasmid loss 
(%) 
    
Wild-type  
S. aureus 14487  
0% 0% 0.5% 
AK02 0.5% 1.5% 1.75% 
AK03 0.75% 2.25% 2.25% 
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3.9. Discussion  
3.9.1. Antimicrobial sensitivity of S. aureus 14487 under energy limitation 
 
This study investigated the effect of energy limitation on the ability of pNZAK1 to confer drug 
resistance after being grown in a nutrient limited environment without antimicrobial selection. 
This phenomenon has previously been observed in S. aureus before where generalised nutrient 
limitation triggered increased antibiotic resistance (74). We therefore hypothesised that 
chemostat imposed energy limitation may alter the gene expression levels of pNZAK1 encoded 
resistance genes leading to altered antimicrobial resistance. However, despite growing cells up 
to 30´ slower than their maximum growth rates to mimic severe nutrient limitations, we 
observed no significant differences in either the MIC or MBC values for ampicillin, fusidic 
acid, mupirocin, and chlorhexidine. This indicates that under our experimental conditions the 
imposition of energy limiting conditions did not impact the cells drug resistance profile to the 
tested antibiotics.  
 
3.9.2 pNZAK1 is maintained in S. aureus 14487 in the absence of antimicrobial selective 
pressure, and in the presence of energy limitation   
 
It is well established that the maintenance of extrachromosomal DNA in the absence of 
selective pressure imposes an energy limitation on the cell (83). There are a number of 
mechanisms by which a plasmid can be maintained in a bacterial host, making it a complex 
system to investigate, these include 1) the plasmid conferring resistance to an antibiotic or 
heavy metal, 2) active partitioning of plasmids randomly in to daughter cells 3) addiction 
systems like toxin/antitoxin systems or bacteriocin system (93,94). In the well characterised 
example of plasmids like pEC156 plasmid derivatives (pIB8) in E. coli with ColE1 toxin, the 
plasmid loss rates do not change in the absence of selective pressure (93). However when the 
addiction system is removed or inhibited e.g. the deletion of gene pcnB which, decreases ColE1 
plasmid maintenance, the plasmid stability is lost (95). 
 
To investigate if S. aureus plasmid pNZAK1 would be lost under energy limiting conditions, 
this study used continuous culture. Despite energy limiting conditions and growth rates up to 
30´ slower than standard batch growth, pNZAK1 was maintained in S. aureus 14487, even 
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without antibiotic selection pressure. While a small population of cells were recovered which 
appeared to have lost plasmid pNZAK1, as determined by whole genome sequencing, at no 
point were these cells able to out compete cells retaining pNZAK1 in the chemostat. However, 
when in stationary phase competition experiments between wild-type cells (pNZAK1+) and 
pNZAK1- cells in rich media (BHI) were carried out, wild-type cells did exhibits a fitness cost. 
This phenomenon previously been shown with this plasmid pNZAK1 in a study by Carter et 
al. (59) 
 
We explored the possibility that if pNZAK1 imposes an energetic burden on S. aureus 14487 
in non-antimicrobial conditions and it is not lost under energy limited conditions, there could 
be an addiction mechanism that is stimulating pNZAK1 maintenance. The pepA1 system and 
lactococcin 972 bacteriocin encoded in pNZAK1 were proposed to be potential plasmid 
maintenance mechanisms. To further elucidate the role of pepA1 and lactococcin 972 in 
plasmid maintenance, both of the genes were deleted using homologous recombination. During 
the excision of modified pKFC vectors; ppep_pKFC and pbac_pKFC, it was shown that CmS 
colonies, colonies that had lost pKFC and potentially the target gene, were periodically also 
AmpS, meaning that they lost pNZAK1. The coinciding loss of pKFC and highly stable 
pNZAK1 suggested that the loss of pKFC and potentially the target gene could decrease 
pNZAK1 stability. However, once both genes were separately deleted and tested for plasmid 
loss the results showed no major increase in plasmid loss in the AK02 or AK03 colonies in 
comparison to wild-type S. aureus 14487. This suggested that the pepA1 system and 
lactococcin 972 bacteriocin system do not play a major role in plasmid maintenance of 
pNZAK1 in S. aureus 14487 in isolation. There could be another mechanism contributing to 
maintenance of pNZAK1 that could work solely or in tandem with the pepA1 and lactococcin 
972 bacteriocin systems. 
 
Further work is required to elucidate the long term stability of pNZAK1 in the population in 
the absence of selective pressure. We propose that there could be an alternative plasmid 
maintenance mechanism present on the plasmid that is yet to be discovered. Potentially, the 
pepA1 system and lactococcin 972 bacteriocin system could play some role, perhaps in 







Investigating the Role of QacA in 







4.1. pNZAK1 and Biocides  
 
In New Zealand, the ST1 lineage of Staphylococcus aureus can contain the plasmid pNZAK1, 
which harbours genes conferring resistance to a number of clinically-important antimicrobials. 
pNZAK1 harbours the mupA and blaZ genes, which confer resistance to the antibiotic 
mupirocin, frequently used as a topical antimicrobial in community and hospital settings, as 
well as b-lactam antibiotics, e.g. ampicillin (59). pNZAK1 also carries the gene qacA, which 
encodes for the multi drug efflux pump QacA. The primary role of QacA is the export of 
antiseptic and disinfectant compounds including quaternary ammonium salts. Given the 
frequent use of sanitisers e.g. chlorhexidine or benzalkonium chloride (BAC) in hospitals it is 
likely that the use of biocides co-selects for the maintenance of pNZAK1 plasmid, and 
therefore  the maintenance of antibiotic resistance genes (40,96). The chromosomally-encoded 
efflux pump NorA has also been shown to increase tolerance to chlorhexidine and other 
biocides (97). The increased tolerance of S. aureus isolates to antiseptics like chlorhexidine 
worldwide has been recorded, however, the exact importance and clinical impact of this 
emergence is unknown (40,55). Elevated MICs from efflux pumps is concerning as it allows 
bacteria to become tolerant to biocides and remain on the skin of patients or surfaces and 
potentially cause infection even after being sanitised (97). In New Zealand S. aureus strains 
the prevalence of qacA is 7% and is associated with the main clonal lineage of S. aureus strains 






Figure 4.1. Schematic representation of the plasmid pNZAK1.  
Genes are denoted by coloured arrows, and the red genes indicate genes of specific interest to 
this investigation. These are as follows: the antibiotic resistance genes encoding resistance to 
mupirocin and b-lactam antibiotics (mupA and blaZ), the antiseptic resistance protein QacA 
(qacA), and two potential plasmid addiction mechanisms (lactococcin 972 bacteriocin and 
pepA1). The mupA and qacA (59) insertion segment is shown in blue. The transposon 552 
insertion segment containing blaZ is shown in orange (sequence information provided by Dr. 
Glen Carter, Doherty Institute, Melbourne) (59).   
 
4.2. QacA genetic regulation and proposed mechanism of action 
 
In S. aureus, tolerance to chlorhexidine can be mediated by the qacA-encoded multidrug efflux 
pump QacA (7). The gene qacA is regulated by qacR, which produces a gene product that 
represses qacA transcription (98). QacA is part of the major facilitator superfamily of efflux 
pumps. QacA functions by utilising the proton motive force (pmf) to pump out substrates like 
quaternary ammonium compounds e.g. CHX (39). QacA confers resistance to biocides like 
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BAC and CHX as well as  a number of dyes, including ethidium bromide (39). QacB is closely 
related to QacA and also found in S. aureus, but has a reduced substrate range (99). However, 
presence of qacA does not necessarily confer resistance to biocides like CHX or BAC (96).  
 
4.3. Hypothesis and Research Objectives  
 
Hypothesis 1: That treatment of S. aureus 14487 with biocides (e.g. chlorhexidine) will alter 
the expression of antimicrobial resistance genes on the plasmid pNZAK1.  
 
Hypothesis 2: That the isogenic S. aureus ∆qacA mutant IM01, which lacks the QacA MDR 
efflux pump, will have increased sensitivity to chlorhexidine and other biocides compared to 
the wild-type S. aureus NZ14487.  
 
These hypotheses will be investigated through the completion of the following objectives: 
 
Research objective 1: RT-qPCR was used to investigate changes in the gene expression of 
qacA, mupA, blaZ, and norA following cell challenge with sub-inhibitory concentrations of 
chlorhexidine. 
 
Research objective 2: To further characterise the role of qacA, antimicrobial sensitivity (MIC) 
and cell-killing assays were conducted to compare the properties of wild-type S. aureus 














4.4. Analysis of gene expression in response to sub-inhibitory chlorhexidine challenge  
 
To investigate the role that key genes found on pNZAK1 may have in antibiotic resistance, we 
examined their expression profiles in response to challenge with sub-inhibitory concentrations 
of chlorhexidine. To do so, RNA was extracted from cells challenged with 0.5´ the MIC of 
chlorhexidine and the gene expression of qacA, mupA, blaZ, and norA was examined by RT-
qPCR (Fig. 4.2). As previously reported the S. aureus housekeeping genes rho (transcription 
termination factor) and rrsC (16s ribosomal RNA) were included in the RT-qPCR as control 
genes to monitor the level of gene expression for genes unaffected by the test compound, and 
were used to calculate the fold change in gene expression of qacA, mup. blaZ, and norA (100). 
All primer pairs were optimised for their binding efficiency assay, and their respective 
efficiencies are shown in Table 4.1. All RT-qPCR primer binding efficiencies were > 90% 
indicating that they have suitable binding efficiencies to the synthesised cDNA.  
 















 a see Table 2.2 for qPCR primer sequences  
  
Primer Namea Slope Value Efficiency 
qacA -3.4 ± 0.1414 
 
96.84% 
mupA -3.5 ± 0.5916 
 
93.07% 
blaZ -3.1 ± 0.2646 
 
110.17 % 
norA -3.4 ± 0.3464 
 
96.84 % 
rho  -3.3 ± 1.852 
 
100.5 % 






















Figure 4.2. Gene expression profile of the qacA, mupA, blaZ, and norA genes from  
S. aureus 14487 after challenge with sub-inhibitory concentrations of chlorhexidine.  
S. aureus 14487 cells were grown to mid-exponential phase (OD600 0.4) and challenged with 
0.5´ the MIC of chlorhexidine (1 µg/mL) for 1 h. cDNA synthesised from treated and non-
treated cells was used to determine the transcript levels for the selected genes by RT-qPCR. 
Log2 fold-changes were calculated relative to untreated controls, and the data was normalised 
relative to a reference gene using the ∆∆CT method (101). The dotted line represents the value 
at which the genes are two-fold overexpressed in the treated cells compared to non-treated. The 
error bars correspond to the standard deviation of the mean from three biological replicates in 
technical triplicate. 
  






























RT-qPCR demonstrated that S. aureus 14487 cells challenged with a sub-inhibitory 
concentration of chlorhexidine (0.5´ MIC) for 1 h, had a 4-fold increase in gene expression of 
qacA, relative to the control genes (Fig. 4.2). The mupA gene expression also increased 2-fold 
in response to chlorhexidine challenge, but no changes were observed in the expression of blaZ. 
Interestingly, an 8-fold increase in the expression of the chromosomally encoded norA efflux 
pump was also observed. These results demonstrate the qacA gene located on plasmid 
pNZAK1 is induced by chlorhexidine at sub lethal concentrations as are mupA and norA. 
 
4.5. Time-dependent cell killing by chlorhexidine against wild-type Staphylococcus aureus 
14487 and the IM01 ∆qacA mutant 
 
To investigate the possible advantageous nature of qacA carriage, wild-type S. aureus 14487 
cells and IM01 ∆qacA cells were challenged with 1´ the MIC of chlorhexidine to examine the 
differences in killing kinetics between the two strains. Cells were grown to mid exponential 
phase and challenged with chlorhexidine, samples were withdrawn, and the cell viability was 
determined by measuring the CFU/mL at each given time point (Fig. 4.3). However, when 
exponentially growing cells at a starting concentration of 1´108 CFU/mL were challenged with 
a known inhibitory concentration of chlorhexidine, no significant differences between wild-
type S. aureus cells and the IM01 ∆qacA mutant were observed. 
 
4.6. Drug sensitivity of wild-type Staphylococcus aureus 14487 versus IM01 to hospital 
disinfectants  
To understand the role which QacA may play in tolerance to the quaternary ammonium 
compound BAC, and the blended disinfectant Trigene, MIC and MBC assays were conducted 
with the wild-type S. aureus 14487, IM01 ∆qacA mutant, and the ATCC strain S. aureus 6528 
which naturally lacks qacA (Table 2.1). The MIC for BAC in wild type S. aureus 14487 was 
2.5 µg/mL, five times higher than the MIC observed in the IM01 strain, and ATCC 6538 where 
the MIC was 0.5 µg/mL (Fig. 4.4A). Likewise, the MBC for the wild-type strain was 5.0 µg/mL 
























Figure 4.3. Time-dependent killing in wild-type S. aureus 14487 and the IM01 ∆qacA 
mutant when challenged with chlorhexidine (1´ MIC, 2 µg/mL) over 24 h. S. aureus cells 
were grown to an OD600 of 0.15 and then challenged with chlorhexidine (2 µg/mL). Samples 
were withdrawn at 0, 1, 2, 3, and 24 h, diluted in PBS, and spotted in 20 µl volumes onto TSA 
to determine the CFU/mL. The experiment was carried out in 100 mL TSB flasks at 37˚C with 

































Figure 4.4. Susceptibility of S. aureus strains to benzalkonium chloride (BAC). (A) To 
investigate the susceptibility to BAC the minimum inhibitory concentration (MIC) was 
determined in TSB after 24 h against the following strains: wild-type, IM01, and ATCC 6538. 
(B) Following MIC assays samples where inhibition was observed were further analysed to 
determine the minimum bactericidal concentration (MBC). This data is representative of a 





























Figure 4.5. Susceptibility of selected S. aureus strains to the disinfectant Trigene. (A) To 
investigate the susceptibility to Trigene the minimum inhibitory concentration (MIC) was 
determined in TSB after 24 hours exposure against the following strains; wild-type, IM01, and 
ATCC 6538 (B) Following MIC assays samples where inhibition was observed were further 
analysed to determine the minimum bactericidal concentration (MBC). This data is 
representative of a biological and technical triplicate. 
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The MIC for Trigene against the wild type S. aureus 14487 was 0.03 % (v/v), while the MIC 
for Trigene for both IM01 ∆qacA mutant and ATCC 6538 strain was 0.01 % (v/v), or three 
times lower (Fig. 4.5A). The Trigene MBC for the wild-type S. aureus cells was 0.06% (v/v) 
two-fold higher than the MBC observed for both the IM01 ∆qacA mutant and S. aureus ATCC 
6538 (Fig. 4.5B). Overall, there appears to be a considerable difference in MIC and MBC of 
BAC and Trigene in strains of S. aureus with and without qacA. 
 
4.7. Time-dependent killing of Staphylococcus aureus 14487 versus IM01 ∆qacA in the 
presence of benzalkonium chloride and Trigene  
 
To further elucidate the importance of qacA in S. aureus, the wild-type strain and the IM01 
∆qacA mutant were grown to mid-exponential phase (OD600 of 0.5) and challenged with BAC 
(1´ MIC, 2.5 µg/mL) or Trigene (1´ MIC, 0.03%[v/v]). Samples were analysed at 0, 0.5, 1, 2, 











































Figure 4.6. Time-dependent killing of wild-type S. aureus 14487 and IM01 ∆qacA mutant 
against BAC and Trigene over 24 h. Wild-type cells (blue line), and IM01 ∆qac mutant (red 
line), were grown to mid-exponential phase (OD600 0.5) in TSB media and challenged with: 
(A) BAC (2.5 µg/mL) (triangle) or (B) Trigene (0.03%[v/v]) (square), untreated cells (circles). 
Samples were taken at times 0, 0.5, 1, 2, 3, and 24 h, diluted in PBS, and spotted in 10 µl 
volume on TSA to determine the CFU/mL. This data is representative of three biological 
replicates and the error bars represent the standard error of the mean. The dotted line represents 
the limit of detection at 103 CFU/mL.  
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When S. aureus was challenged with 1´ MIC BAC (Fig. 4.6A) for 1 h, the wild-type S. aureus 
and IM01 mutant had the same CFU/mL of ~1 x 108 1 h after challenge whereas the untreated 
cells were 2.6´108. After 24 h the CFU/ml of non-treated cells and cells challenged with 1´ 
MIC BAC were around 2-4´1010. This suggests that there is a slight difference between non-
treated cells and cells treated with 1´BAC. However, there is not a significant difference 
between wild-type strains with QacA+ and the IM01 QacA- mutant in response to challenge 
with BAC (1´ MIC).. 
 
 There was a substantial difference between wild-type CFU/mL and IM01 mutant strain 
CFU/mL when challenged with 1´ MIC Trigene (0.03% v/v) (Fig. 4.6B). After 1 h, the 
CFU/mL of the IM01 mutant dropped below the limit of detection, while the wild-type  
S. aureus CFU/mL remained fixed between 1´107 and 1´108 between the 1 h and 4 h 
timepoints. At 24 h, the CFU/mL of 1´ MIC Trigene wild-type S. aureus had increased to 
1´109 CFU/mL, close to that of the non-treated wild-type S. aureus at 1´1010 CFU/mL. 
Conversely, at the 24 h timepoint the CFU/mL of 1´ MIC Trigene IM01 mutant increased 
above the limit of detection to ~ 1´103 CFU/mL. This highlights the difference between S. 
aureus strains that lack qacA and how they tolerate some antimicrobial compounds.  
 
4.8. Chemical compound library screening to further investigate the gene function of 
qacA 
 
To further understand the gene function of qacA, we screened the FDA-approved Drug Library 
(Selleckchem), which contains 1399 FDA-approved drugs (including antibiotics and 
antiseptics). As QacA has many possible substrates, by identifying compounds which work 
more effectively against the ∆qacA mutant relative to the wild type S. aureus cells provides 
insight into compounds which are recognised by QacA. Additionally, to further investigate the 
effect of these compounds on S. aureus 14487, an isogenic pNZAK1- mutant, AK01, was also 
challenged with selected inhibitory compounds (see section 3.1 for the generation of this 
∆pNZAK1 strain isolate). Chemical library screening was carried out as specified in section 
2.11 in 96-well plates with 25 µM of each FDA compound used. OD600 values were recorded 
for each strain after challenge, and were compared to non-treated control cells. The antibiotic 
vancomycin was used a positive control. When S. aureus was screened against the FDA-
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compound library at 25 µM, excellent mean Z′ and Z-factors were returned (e.g. S. aureus Z′ 
= 0.657-0.923, Z-factor = 0.648-0.977). Whereby Z-factor values 1 > Z > 0.5 indicates ‘an 
excellent assay (82). 
 
4.8.1. Screening of FDA compound library against IM01 ∆qacA mutant and wild-type S. 
aureus 
 
To identify potent substrates of QacA, the FDA compound library was screened against wild-
type S. aureus and the IM01 mutant (Table 2.1). Nine compounds were identified from the 
FDA compound library that inhibited growth (OD600) of the ∆qacA mutant by more that 50% 
relative to wild-type cells. These compounds are as follows:   
 
¨ Cephalothin Sodium is a first generation cephalosporin and is a bactericidal b-lactam 
antibiotic that works in the presence of penicillinase-producing bacteria (102).  
¨ Cefamandole is a cephalosporin b-lactam antibiotic active against Gram-positive and 
Gram-negative bacteria (103). 
¨ Carmofur (1-hexylcarbamoyl-5-fluorouracil) is a derivative of fluorouracil used to 
treat colorectal cancer (104).  
¨ Bexarotene is a retinoid X receptor agonist used in cancer treatment (105).   
¨ Pentamidine is a derivative of amidine and is shown to have antiprotozoal and 
antifungal properties (106,107). 
¨ Nifuroxazide is a nitrofuran antibiotic and member of benzoic acids. It has been shown 
to have anti-diarrhoeal properties and can help treat colitis (108).  
¨ Benzbromarone is a uricosuric compound used in treating gout (109).   
¨ Clarithromycin is a macrolide antibiotic that binds to the 50S subunit of the ribosome 
inhibiting protein synthesis (110). 
¨ Rufloxacin hydrochloride is a fluoroquinolone antibiotic which targets the 






























Figure 4.7. Screening of FDA-drug approved compounds against S. aureus 14487 wild-
type and IM01 ∆qacA mutant cells. To investigate the susceptibility of the strains; S. aureus 
14487 and the IM01 mutant to FDA compounds, the OD600 of each strain was recorded after 
challenge with 25 µM of each compound. The starting OD600 was 0.05 in TSB, the cells were 
then challenged and grown at 37˚C and 200 rpm for 18h. The OD600 values were recorded using 
a Thermo multiscan FC platereader. On the right-hand side, the OD600 of untreated and 
vancomycin treated cells are shown. Vancomycin was used at a concentrations of 27.6 µM (40 




Nine compounds (Tables 4.2 and 4.3) inhibited growth of the IM01 mutant relative to the wild-
type S. aureus cells by greater than 50%. Data from the chemical library screening at a fixed 
compound concentration of 25 µM is shown in Fig. 4.7 At 25 µM cephalothin and rufloxacin 
showed the biggest difference in OD600 between wild-type and the IM01 mutant. To confirm 
how many compounds were more active against IM01 compared to wild-type, we determined 




Table 4.2. Antimicrobial sensitivity (MIC) of FDA compounds against S. aureus 14487 and 


















aThe MIC values shown are representative of technical and biological triplicates. Minimum inhibitory 
concentration testing was carried out in Mueller Hinton broth medium, at 37˚C. and 200 rpm. The initial 
inoculation OD600 was 0.0007. The compound range tested was 0.125-256 µg/ml which is relative to 
0.15-640 µM for each compound.  
b Chlorhexidine was included as a positive control to insure the MIC assay was accurate  
 MIC (µg/mL) a 
 
Compound Wild-Type IM01 
Cephalothin 0.25 (0.598 µM) 0.25 (0.598 µM) 
Cefamandole 8 (15 µM)  8 (15 µM) 
Carmofur 0.25 (0.972 µM) 0.25 (0.972 µM) 
Pentamidine 128 (216 µM) 16 (27 µM) 
Nifuroxazide 2 (7.27 µM) 2 (7.27 µM) 
Clarithromycin 0.125 (0.167 µM) 0.125 (0.167 µM) 
Rufloxacin 1 (2.5 µM) 1 (2.5 µM) 
Chlorhexidine b          2 (2.2 µM) 1-2 (~1.1-2.2 µM) 
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Derivative of fluorouracil (104,115) 
Bexarotene 
 
Retinoid X receptor agonist (105,116) 
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Derivative of amidine and is shown to 
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Figure 4.8. Susceptibility of S. aureus 14487 isolates to pentamidine. (A)To investigate the 
susceptibility of the strains; S. aureus 14487, IM01 ∆qacA mutant, and AK01 pNZAK1- mutant 
to pentamidine the minimum inhibitory concentration (MIC) was determined in TSB after 24 
h. (B) Following the MIC assays samples where inhibition was observed were further analysed 
to determine the minimum bactericidal concentration (MBC). This data is representative of a 




The drug sensitivity of S. aureus 14487 was measured using MIC and MBC assays (Fig. 4.8). 
The MIC of pentamidine in wild type S. aureus 14487 cells was between 64 and 128 µg/mL 
and the MBC was between 128 and 256 µg/mL. The MIC of pentamidine in S. aureus 14487 
IM01 and AK01 isolates was between 8 to 16 µg/mL and the MBC was between 16 and 32 
µg/mL. There was a considerable difference in MIC and MBC between the wild type S. aureus 
14487 cells that have qacA in comparison to the IM01 and AK01 cells.  
 
There was a difference between the OD600 values from the high throughput FDA compound 
screening as it uses one standard concentration of 25 µM therefore the result is yes or no for 
activity whereas MIC is carried out with a range of concentrations. The screening is also carried 
out in TSB and not MHB, MHB is more suitable for antimicrobial sensitivity testing than TSB. 
The screening was also done with a higher starting OD600 of 0.05 compared to 0.0007 leading 
to decreased sensitivity of the assay.  
 
4.9. Discussion  
 
4.9.1. Gene expression of qacA, mupA, and norA increased by sub-inhibitory 
chlorhexidine challenge 
 
Typically antimicrobial resistance genes are upregulated in response to antibiotics or 
antiseptics, as the fitness cost of constitutively expressing antimicrobial genes is not necessarily 
advantageous (122). To examine gene expression of the plasmid-encoded antimicrobial 
resistance genes qacA, mupA, blaZ, and norA. S. aureus 14487 cells were challenged with sub-
lethal concentrations of chlorhexidine (Fig. 4.2). Chlorhexidine exposure induced a 4-fold 
increase in the expression of qacA, a 2-fold increase mupA expression, as well as an 8-fold 
increase in the gene expression of norA. The gene norA has previously be shown to be 
overexpressed after treatment with biocides like chlorhexidine or BAC (123). These data 
indicate that the qacA, mupA, and norA promoters are inducible by chlorhexidine. However, 
chlorhexidine did not induce gene expression of blaZ. This could be due to the post-
transcriptional regulation of blaZ by blaRI meaning that a change in RNA levels would not be 
observed after the addition of chlorhexidine (124). These data suggest that antibiotic resistance 
genes like qacA, mupA and norA are inducible by compounds like chlorhexidine even at sub-
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lethal concentrations. Our data highlights that the use of chlorhexidine sanitisers in healthcare 
settings could potentially select for the survival of QacA+ isolates over QacA- isolates. This 
selection pressure in healthcare settings is concerning as selection of S. aureus isolates 
containing qacA on pNZAK1 also selects for mupirocin and  b-lactam resistance as well. 
Studies have previously shown the qacA+ strains outcompete qacA- strains in decolonisation 
studies and that MRSA clone CC22 carrying qacA were more likely to have elevated MICs to 
CHX (125).   
 
4.9.2. The loss of QacA increases drug susceptibility   
 
The objective of this research was to further understand the properties of qacA with a focus on 
investigating the function of qacA in antimicrobial sensitivity. To do so we compared the 
growth properties of wild-type S. aureus 14487 with that of an isogenic mutant IM01 that lacks 
qacA. When we examined the growth of wild-type S. aureus 14487 compared to the IM01 
mutant in the presence of chlorhexidine (Fig. 4.3) we observed that there was no significant 
difference between the two isolates ability to grow, despite chlorhexidine being a known 
substrate for QacA (57,126). This could be due to the overexpression of the NorA efflux pump 
which has also been shown to efflux similar substrates to QacA like chlorhexidine (96,97). To 
further explore the role of QacA. We examined two biocides typically used in hospital settings, 
these being Trigene and BAC. Additionally, on the basis of results from high-throughput 
screening of the FDA-approved drug library we also investigated the antimicrobial properties 
of pentamidine in both the wild-type and IM01 mutant cells. Where no difference was observed 
for chlorhexidine, the BAC and Trigene MIC and MBC values were markedly higher in wild-
type S. aureus 14487 cells in comparison to the IM01 mutant (Fig. 4.4 and 4.5). However, 
time-dependent cell killing assays showed no significant difference between wild-type  
S. aureus 14487 and IM01 after treatment with 1´ MIC BAC (Fig. 4.6). Conversely, after 
treatment with 1´ MIC Trigene there was a noteworthy difference between S. aureus 14487 
cells with qacA and those without. The CFU/mL of cells lacking qacA was reduced after 1 h 
while the wild-type S. aureus 14487 cells were only inhibited. Furthermore, wild-type S. 
aureus 14487 was able to grow up to non-treated CFU/mL levels after 24 h while the IM01 
mutant only grew slightly about the limit of detection. This data supported the idea that QacA 
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conferred a survival benefit in environments with extensive selective pressure of antimicrobial 
sanitiser.  
 
The third compound appeared to be more effective against cells that lack qacA was 
pentamidine. Pentamidine is a FDA compound used to treat the parasite Trypanosoma brucei 
and the fungus Pneumocystis jirovecii (127). Pentamidine is traditionally not associated with 
S. aureus, however, the fact that it is a substrate for QacA is of interest. The mechanism of 
pentamidine has not been confirmed for all species, but it is speculated to target the DNA 
synthesis pathway (128). The MIC of pentamidine increased from 8-16 µg/mL in the IM01 
mutant to 64-128 µg/mL in wild-type cells. The MBC of pentamidine increased from 16-32 
µg/mL in the IM01 mutant to 128-256 µg/mL in wild-type cells. The difference in MIC and 
MBC between wild-type S. aureus 14487 and the IM01 mutant emphasises that the sensitivity 
of pentamidine is reduced by the presence of qacA (Fig. 4.8). This data demonstrates the 
extensive range of substrate that QacA has and why it is such a problematic multi-drug efflux 
pump as it exhibits resistance to even non-bactericidal compounds like pentamidine, which is 
on the WHO list of essential medicines. This emphasises how vital the investigation of QacA 
is, as it is located on a mobile genetic element (pNZAK1) and can be easily transferred between 
isolates and with the added selection pressure of antimicrobial sanitisers. As such, the 
prevalence of qacA in bacteria will most likely only increase (59,96). The spread of antiseptic 
resistance could become more of a burden to the healthcare system, increase hospital acquired 
infections and potentially even fatalities from drug resistance infections (59,96). 
 
 4.10. General Conclusions  
 
This study has illustrated the need to further understand qacA and its role in antiseptic 
resistance. The fact that qacA is encoded on a plasmid with additional antibiotic resistance 
genes such as mupA and blaZ only increases the need for further research. This study has shown 
that sub-MIC levels of chlorhexidine are able to stimulate gene expression of qacA, mupA, and 
norA. By allowing the potential selection of QacA+ strains over QacA- strain in healthcare 
settings, where antiseptic sanitisers are widely used, we are fostering an environment for 
tolerance to occur to essential compounds. Moreover, we have highlighted that carriage of 
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qacA. can increase survival over isolates that lack qacA. Antiseptic selection pressure creates 
an environment that selects for qacA isolates to become more frequent in S. aureus strains.  
 
The multi-drug efflux pump QacA is encoded in pNZAK1, a MDR plasmid found in S. aureus 
worldwide. This study demonstrates that despite the fitness costed imposed by pNZAK1 the 
plasmid is still highly stable in S. aureus 14487 even in energy limiting conditions, and in the 
absence of antibiotic selection. Additionally, that even though pNZAK1 was shown to confer 
a fitness cost it is very stable in S. aureus 14487. Further clarifying the pNZAK1 maintenance 
mechanism in S. aureus is vital to be able to reduce the spread of multi-drug resistance plasmids 
in healthcare settings.  
 
4.11. Future directions  
 
The role of qacA in antiseptic tolerance is still not fully understood. The effect of efflux pump 
inhibitors like verapamil is undetermined and could possibly be used in synergy with 
compounds that are more effective against ∆qacA isolates. Antiseptic solutions could be 
developed that contain efflux pump inhibitors to resensitise QacA+ isolates. To investigate 
potential synergy between BAC/Trigene and other potential compounds we could carry out 
another screen with wild-type and IM01. Additionally, we could generate IMV and test 
fluorescent ethidium bromide in a quenching assays to look for compounds that inhibit QacA.  
 
The maintenance of pNZAK1 is still unknown. Other possible plasmid maintenance 
mechanisms need to be identified. There could be multiple mechanisms working tandem to 
generate a highly stable plasmid even though it confers a fitness cost. Possible genes could be 
identified through the use of RNAseq or Tn mutagenesis, where cells from the chemostat are 
sequenced and genes with high expression unrelated to metabolism or general cell stress could 
be analysed as potential candidates. Potentially, a double knockout could also be generated to 
explore the idea of both addiction mechanisms working in together. Another possibility is to 




Appendix A: Media  
A.1 Luria Broth for growth of E. coli 
To 1 L of distilled water add:  
10 g/L tryptone 
5 g/L yeast extract 10 g/L of NaCl2  
For LB agar add 15 g/L of bacto agar (Sigma-Aldrich)  
A.2 ¼ Mueller Hinton Broth for growth of S. aureus  
To 1 L of dH2O add:  
¼ of recommend amount of powder for Mueller Hinton cation-adjusted broth (Becton 
Dickinson) and diluted into dH2O. 












Appendix B: qPCR plate layout  
 
Table 4.4. Layout of RT-qPCR primer efficiency 
 
 
 Primer Name     
 1 2 3 4 5 
cDNA 
Dilution 




A  norA NT  
500 nM 
norA NT  
500 nM 
norA NT  
500 nM 
norA NT  
500 nM 
norA NT  
500 nM 
B norA CHX 500 
nM 
norA CHX  
500 nM 
norA CHX  
500 nM 
norA CHX 
 500 nM 
norA CHX  
500 nM 
C qacA NT  
500 nM 
qacA NT  
500 nM 
qacA NT  
500 nM 
qacA NT  
500 nM 
qacA NT  
500 nM 
D qacA CHX  
500 nM 
qacA CHX  
500 nM 
qacA CHX  
500 nM 
qacA CHX  
500 nM 
qacA CHX 500 
nM 
E rho NT  
500 nM 
rho NT  
500 nM 
rho NT  
500 nM 
rho NT  
500 nM 
rho NT  
500 nM 
F rrsC NT  
500 nM 
rrsC NT  
500 nM 
rrsC NT  
500 nM 
rrsC NT  
500 nM 










































A NT1 NT1 NT1 NT1 NT1 NT1 NT1 NT1 NT1 
B “ “ “ “ “ “ “ “ “ 
C “ “ “ “ “ “ “ “ “ 
D CHX1 CHX1 CHX1 CHX1 CHX1 CHX1 CHX1 CHX1 CHX1 
E “ “ “ “ “ “ “ “ “ 
F “ “ “ “ “ “ “ “ “ 
G H2O “ “ “ “ “ “ “ 
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